WO2022168055A1 - Extracellular vesicle drug analysis for real-time monitoring of targeted therapy - Google Patents
Extracellular vesicle drug analysis for real-time monitoring of targeted therapy Download PDFInfo
- Publication number
- WO2022168055A1 WO2022168055A1 PCT/IB2022/051088 IB2022051088W WO2022168055A1 WO 2022168055 A1 WO2022168055 A1 WO 2022168055A1 IB 2022051088 W IB2022051088 W IB 2022051088W WO 2022168055 A1 WO2022168055 A1 WO 2022168055A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- probe
- evs
- binding
- sensor
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 493
- 229940079593 drug Drugs 0.000 title claims abstract description 490
- 238000012544 monitoring process Methods 0.000 title abstract description 26
- 238000004458 analytical method Methods 0.000 title description 113
- 238000002626 targeted therapy Methods 0.000 title description 10
- 239000000523 sample Substances 0.000 claims abstract description 459
- 238000000034 method Methods 0.000 claims abstract description 123
- 238000002372 labelling Methods 0.000 claims abstract description 94
- 238000006243 chemical reaction Methods 0.000 claims abstract description 48
- 230000003321 amplification Effects 0.000 claims abstract description 47
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 47
- 238000011065 in-situ storage Methods 0.000 claims abstract description 26
- 230000027455 binding Effects 0.000 claims description 146
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 117
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 117
- 238000011282 treatment Methods 0.000 claims description 109
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 108
- 239000002063 nanoring Substances 0.000 claims description 73
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 59
- 239000003795 chemical substances by application Substances 0.000 claims description 58
- 229960001686 afatinib Drugs 0.000 claims description 57
- 208000020816 lung neoplasm Diseases 0.000 claims description 47
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 46
- 201000005202 lung cancer Diseases 0.000 claims description 46
- 230000003287 optical effect Effects 0.000 claims description 41
- 239000000758 substrate Substances 0.000 claims description 41
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 34
- 229940121647 egfr inhibitor Drugs 0.000 claims description 34
- 102000004190 Enzymes Human genes 0.000 claims description 32
- 108090000790 Enzymes Proteins 0.000 claims description 32
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 28
- 229960001433 erlotinib Drugs 0.000 claims description 28
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 28
- 239000000439 tumor marker Substances 0.000 claims description 25
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 24
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 24
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 24
- 102100034256 Mucin-1 Human genes 0.000 claims description 24
- 230000002255 enzymatic effect Effects 0.000 claims description 24
- 239000002131 composite material Substances 0.000 claims description 21
- 229960003278 osimertinib Drugs 0.000 claims description 18
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims description 18
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 claims description 17
- -1 CNX2006 Chemical compound 0.000 claims description 16
- 239000002086 nanomaterial Substances 0.000 claims description 16
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 claims description 15
- ITTRLTNMFYIYPA-UHFFFAOYSA-N WZ4002 Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1OC1=CC=CC(NC(=O)C=C)=C1 ITTRLTNMFYIYPA-UHFFFAOYSA-N 0.000 claims description 11
- 239000011521 glass Substances 0.000 claims description 11
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 claims description 10
- 229950002205 dacomitinib Drugs 0.000 claims description 10
- 239000013068 control sample Substances 0.000 claims description 8
- 230000005714 functional activity Effects 0.000 claims description 7
- 238000012417 linear regression Methods 0.000 claims description 6
- 238000005286 illumination Methods 0.000 claims description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 68
- 210000004369 blood Anatomy 0.000 abstract description 32
- 239000008280 blood Substances 0.000 abstract description 32
- 238000003556 assay Methods 0.000 abstract description 26
- 230000002860 competitive effect Effects 0.000 abstract description 24
- 238000005516 engineering process Methods 0.000 abstract description 22
- 230000036962 time dependent Effects 0.000 abstract description 12
- 238000000059 patterning Methods 0.000 abstract description 8
- 150000003384 small molecules Chemical class 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 122
- 206010028980 Neoplasm Diseases 0.000 description 62
- 238000005259 measurement Methods 0.000 description 49
- 210000002381 plasma Anatomy 0.000 description 45
- 201000011510 cancer Diseases 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 36
- 238000001514 detection method Methods 0.000 description 34
- 239000003550 marker Substances 0.000 description 31
- 230000005540 biological transmission Effects 0.000 description 30
- 230000001413 cellular effect Effects 0.000 description 30
- 239000000047 product Substances 0.000 description 30
- 229940088598 enzyme Drugs 0.000 description 29
- 230000008859 change Effects 0.000 description 24
- 238000007306 functionalization reaction Methods 0.000 description 22
- 230000003389 potentiating effect Effects 0.000 description 21
- 230000003595 spectral effect Effects 0.000 description 21
- URYYVOIYTNXXBN-OWOJBTEDSA-N trans-cyclooctene Chemical compound C1CCC\C=C\CC1 URYYVOIYTNXXBN-OWOJBTEDSA-N 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 20
- 239000010931 gold Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 230000003993 interaction Effects 0.000 description 18
- 230000035772 mutation Effects 0.000 description 18
- 238000002965 ELISA Methods 0.000 description 17
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 17
- 229910052737 gold Inorganic materials 0.000 description 17
- 238000012512 characterization method Methods 0.000 description 16
- 239000003596 drug target Substances 0.000 description 16
- 238000000684 flow cytometry Methods 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 230000000977 initiatory effect Effects 0.000 description 13
- 230000000737 periodic effect Effects 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000005754 cellular signaling Effects 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 238000001228 spectrum Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 11
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 11
- 239000012472 biological sample Substances 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 150000001540 azides Chemical class 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 238000012650 click reaction Methods 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 230000008020 evaporation Effects 0.000 description 10
- 238000004896 high resolution mass spectrometry Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 102100027221 CD81 antigen Human genes 0.000 description 9
- 108091054442 EV proteins Proteins 0.000 description 9
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 239000013592 cell lysate Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000001878 scanning electron micrograph Methods 0.000 description 9
- 238000004088 simulation Methods 0.000 description 9
- 102100037904 CD9 antigen Human genes 0.000 description 8
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 8
- 108010021466 Mutant Proteins Proteins 0.000 description 8
- 102000008300 Mutant Proteins Human genes 0.000 description 8
- 230000001028 anti-proliverative effect Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 230000005672 electromagnetic field Effects 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 101710113864 Heat shock protein 90 Proteins 0.000 description 7
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 7
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 description 7
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 7
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 7
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 description 7
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 7
- 238000000151 deposition Methods 0.000 description 7
- 230000008021 deposition Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 102000010660 flotillin Human genes 0.000 description 7
- 108060000864 flotillin Proteins 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000012800 visualization Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 101000836492 Dictyostelium discoideum ALG-2 interacting protein X Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101001134621 Homo sapiens Programmed cell death 6-interacting protein Proteins 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- WRRMXPJFEJYDSW-UFLZEWODSA-N 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid tetrazine Chemical compound N1=NN=NC=C1.OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12 WRRMXPJFEJYDSW-UFLZEWODSA-N 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000003917 TEM image Methods 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000002790 cross-validation Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000012474 protein marker Substances 0.000 description 5
- 238000004626 scanning electron microscopy Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000000609 electron-beam lithography Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000010249 in-situ analysis Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000001459 lithography Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000011896 sensitive detection Methods 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 238000010989 Bland-Altman Methods 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 206010013710 Drug interaction Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000007987 MES buffer Substances 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000012575 bio-layer interferometry Methods 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000013211 curve analysis Methods 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 230000004001 molecular interaction Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920002120 photoresistant polymer Polymers 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000011894 semi-preparative HPLC Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 238000004627 transmission electron microscopy Methods 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- GMODTLPHFKLRNF-ALUKSYHCSA-N CN(C)C/C=C/C(NC(C=C1C(NC(C=C2)=CC(Cl)=C2F)=NC=NC1=C1)=C1OCCCNC(CNC(OC1CC/C=C/CCC1)=O)=O)=O Chemical compound CN(C)C/C=C/C(NC(C=C1C(NC(C=C2)=CC(Cl)=C2F)=NC=NC1=C1)=C1OCCCNC(CNC(OC1CC/C=C/CCC1)=O)=O)=O GMODTLPHFKLRNF-ALUKSYHCSA-N 0.000 description 2
- 108010056891 Calnexin Proteins 0.000 description 2
- 102000034342 Calnexin Human genes 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 238000000719 MTS assay Methods 0.000 description 2
- 231100000070 MTS assay Toxicity 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- OUGQJOKGFAIFAQ-OWOJBTEDSA-N [(4e)-cyclooct-4-en-1-yl] (2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)OC1CCC\C=C\CC1 OUGQJOKGFAIFAQ-OWOJBTEDSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001085 differential centrifugation Methods 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 2
- 229950007440 icotinib Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 238000000302 molecular modelling Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 210000004910 pleural fluid Anatomy 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000006557 surface reaction Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002849 thermal shift Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000000411 transmission spectrum Methods 0.000 description 2
- ZDHXKXAHOVTTAH-UHFFFAOYSA-N trichlorosilane Chemical compound Cl[SiH](Cl)Cl ZDHXKXAHOVTTAH-UHFFFAOYSA-N 0.000 description 2
- 239000005052 trichlorosilane Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- WONRDHPFOHAWOG-UHFFFAOYSA-N 2-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=C(Cl)C=CC2=C1 WONRDHPFOHAWOG-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- KJDSORYAHBAGPP-UHFFFAOYSA-N 4-(3,4-diaminophenyl)benzene-1,2-diamine;hydron;tetrachloride Chemical group Cl.Cl.Cl.Cl.C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 KJDSORYAHBAGPP-UHFFFAOYSA-N 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- SOCHAVZCSUVQAX-UHFFFAOYSA-N CC(C)(C)OC(NCCCOC(C=C(C1=C2)N=CN=C1NC(C=C1)=CC(Cl)=C1F)=C2N)=O Chemical compound CC(C)(C)OC(NCCCOC(C=C(C1=C2)N=CN=C1NC(C=C1)=CC(Cl)=C1F)=C2N)=O SOCHAVZCSUVQAX-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 238000003236 bicinchoninic acid assay Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 210000002726 cyst fluid Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000005328 electron beam physical vapour deposition Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000003312 immunocapture Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 238000010234 longitudinal analysis Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004908 prostatic fluid Anatomy 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 238000002174 soft lithography Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- XDJCYKMWJCYQJM-UHFFFAOYSA-N tert-butyl n-(3-hydroxypropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCO XDJCYKMWJCYQJM-UHFFFAOYSA-N 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- NQPHMXWPDCSHTE-UHFFFAOYSA-N trifluoromethanesulfonyl azide Chemical compound FC(F)(F)S(=O)(=O)N=[N+]=[N-] NQPHMXWPDCSHTE-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0893—Geometry, shape and general structure having a very large number of wells, microfabricated wells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0896—Nanoscaled
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- this disclosure provides a method of measuring the binding of a drug to a target in a subject that has been treated with a drug over a treatment period, wherein the method comprises: contacting a probe with extracellular vesicles (EVs) from samples obtained from the subject at different time points of the treatment period, wherein the probe is capable of competing with the drug in binding to the target in the EVs, and detecting the binding of the probe to the EVs in the samples, wherein a decrease in the binding of the probe to the EVs as treatment period progresses indicates an increase in the binding of the drug to the target in the subject.
- EVs extracellular vesicles
- contacting the probe with EVs from the samples obtained from the subject comprises: for each sample, i) contacting the EVs from the sample with a sensor, wherein the EVs are captured to the sensor, ii) contacting the probe with the EVs captured on the sensor, wherein the probe binds to target molecules on the EVs that are not already bound by the drug, wherein the probe’s binding to the target molecules results in a signal P.
- the signal P is in situ enzymatic amplification of signal corresponding to the binding of the probe to the target molecules.
- this disclosure provides a method of comparing the potency of a first drug relative to a second drug on a subject comprising: contacting the first drug and the second drug with extracellular vesicles (EVs) obtained from a sample of the subject separately, adding a probe to the EVs that have been contacted with the first drug and to the EVs that have been contacted with the second drug, wherein the probe is capable of competing with both the first drug and the second drug in binding to the target molecules in the EVs, and detecting the binding of the probe to the EVs that have been contacted with the first drug and EVs that have been contacted with the second drug, wherein a lower binding of the probe to the EVs that have been contacted with the first drug relative to the second drug indicates that the first drug is more potent than the
- the contacting the EVs with varying increasing concentrations of a first drug and a second drug contacting the EVs that have been contacted with varying increasing concentrations of the first or the second drug with a probe, determining the drug occupancy at each concentration of the first and second drug, determining an IC 50 of the drug occupancy of the first drug and an IC 50 of the drug occupancy of the second drug, determining that the first drug is more potent than the second drug if the IC 50 of the drug occupancy of the first drug is lower than that of the second drug, or determining the first drug is less potent than the second drug if the IC 50 of the drug occupancy of the first drug is higher than that of the second drug.
- this disclosure provides a method of detecting mutations in EGFR in a subject, the method comprising: i) contacting an EV sample from a patient with a drug that targets the wild type EGFR, ii) adding a probe to the EVs samples that have contacted with the drug, wherein the probe is capable of competing with the drug in binding to the wild type EGFR iii) determining an IC 50 of drug occupancy for EVs from the patient as compared to that of control EVs expressing the wild type EGFR, and iv) determining that the subject has a mutation in the EGFR if the IC 50 of drug occupancy for the EV sample from the patient is less than the IC 50 of drug occupancy for the control EVs.
- the EVs are captured on the sensor via binding to a capture agent immobilized on the sensor.
- the capture agent is an antibody that is against one or more proteins selected from the group consisting of CD63, CD81, CD9, HER2, LAMP-1, Alix, HSP90, an Flotillin 1, a TSG101, EGFR, EpCAM, and MUC1.
- the disclosure provides a method of diagnosing a lung cancer in a subject, the method comprising: contacting a probe with extracellular vesicles (EVs) from a sample obtained from the subject, wherein the EVs are captured by a capture agent immobilized on a sensor, wherein the capture agent binds to a cancer marker on the EVs, wherein the cancer marker is preferentially expressed in lung cancer than normal cells, wherein the probe binds to EGFR on the EVs, wherein the binding of the capture agent to the cancer marker does not substantially interfere with the binding of the probe to the cancer marker on the EVs, detecting a signal associated with binding of the probe to the EVs, and determining subject has the lung cancer if the signal is greater than a control.
- EVs extracellular vesicles
- the cancer marker is selected from the group consisting of MUC1, EpCAM, and EGFR.
- this disclosure provides a sensing element comprising nanogap structures patterned on a conductive layer that is deposited on a glass substrate, wherein the nanogap structures are patterned to form nanogaps between adjacent nanostructures, and wherein the average size of nanogap is 20 to 500 nm, wherein illumination of the nanogap structures produces a surface plasmon resonance.
- the nanogap structures are nanorings, wherein the nanogaps are formed between an outer circular shape and an inner circular shape wherein the outer circular shape has an outer diameter in a range from 200 nm to 500 nm, and /or the inner circular shape has an inner diameter in a range from 30 nm to 250 nm.
- the conductive layer comprises a material selected from the group consisting of a silver, gold, copper, titanium, aluminum, and chromium. [13] In some emboidments, this disclosure provides a sensor comprising an array of any of the sensing element described above.
- this disclosure provides a microfluidic system comprising: a flow cell, wherein the flow cell comprises a sensor array comprising a plurality of sensing elements of embodiment 29, microfluidic channels for introducing samples into the sensor array; and a light source, wherein the light source is arranged to illuminate the sensor array.
- this disclosure provides a probe that is capable of competing with a drug in binding to its target, wherein the probe contains a tag, wherein the tag can ligate to an enzyme, and wherein the enzyme is capable of catalyzing a reaction to produce an insoluble optical product and producing a detectable signal.
- the probe is a click probe.
- the click probe ligates to the enzyme through a copper-free click reaction.
- the enzyme is conjugated to tetrazine or dibenzocyclooctyne (DBCO).
- DBCO dibenzocyclooctyne
- the enzyme is tetrazine-conjugated horseradish peroxidase (HRP).
- HRP horseradish peroxidase
- the EGFR inhibitor disclosed herein is selected from the group consisting of afatinib, osimertinib, erlotinib, dacomitinib, CNX2006, and WZ4002.
- FIG. 1A ExoSCOPE schematics. Drug-bound protein receptors are secreted through nanoscale extracellular vesicles (EVs). To measure EV drug occupancy and cellular drug effects, the ExoSCOPE platform utilizes competitive target labeling of EVs by bio-orthogonal click probes. These probes recruit enzymes (horseradish peroxidase) to achieve in situ deposition of insoluble optical products on labeled vesicles, thereby amplifying the probe-labeling signal.
- FIG. 1B Spatial patterning of ExoSCOPE molecular reactions within plasmonic resonators. EVs are protein-typed and probe-amplified within plasmonic nanoring gaps, to exploit local electromagnetic hotspots for sensitive detection.
- FIG. 1C Characterization of an ExoSCOPE click probe. Molecular docking simulation shows probe binding to the active site (red box) of EGFR kinase domain. The magnified view illustrates the probe in yellow and the parent drug (afatinib) in grey. Inset: transmission electron micrograph (TEM) of in situ vesicle labeling by the probe.
- TEM transmission electron micrograph
- FIG.1D Plasmonic nanoring resonators. Left: scanning electron micrographs (SEM) of periodic lattices of gold nanorings, fabricated on a glass substrate. Right: enhanced electromagnetic fields are simulated to locate within the nanoring gaps (top), according to the measured cross-sectional dimensions of the nanorings (bottom).
- FIG.1E Real-time monitoring of targeted therapy in lung cancer patients. ExoSCOPE was applied to evaluate drug dynamics in cancer-associated EVs, directly in blood samples. In comparison to conventional blood pharmacologic analysis (PK/PD), ExoSCOPE could effectively distinguish treatment outcome. [18] FIG.2A-2E. Design and evaluation of click probes.
- FIG.2A Structures of the synthesized click probes.
- the parent drug afatinib
- the probe handles and linkers are respectively colored; their corresponding reporters can be found in FIG.12.
- FIG.2B Anti-proliferation activities of the click probes.
- Lung cancer cells H3255
- probe A3 showed improved lipophilicity (calculated distribution coefficient at pH 7.4, cLogD) and functional activity (GI50).
- FIG. 2C Live-cell labeling.
- FIG. 2D Real-time binding kinetics of probe A3 with different EGFR mutant proteins. We immobilized and incubated probe A3 with cell lysates containing different EGFR mutant proteins.
- FIG. 3A-3F Multiparametric analysis of EV drug occupancy.
- FIG. 3A Molecular characterization of A3 labeling in EVs. Left: SEM of EVs immuno-captured on a microbead through anti-CD63 antibody. Scale bar, 500 nm. Right: flow cytometry analysis of bead-bound EVs, after in situ probe labeling (100 nM) and click reaction with Cy5 reporter. FSC, forward scatter.
- FIG. 3B Probe amplification within plasmonic nanoring resonators. Left: finite-difference time-domain simulations.
- FIG. 3C Detection sensitivity of the ExoSCOPE in-ring assay. The limit of detection was determined by titrating a known amount of EVs and measuring their A3 probe labeling signal through anti-CD63 vesicle capture.
- FIG. 3D Quantification of EGFR expression in EVs. Using EVs derived from various cell lines with known levels of EGFR expression, we measured the ExoSCOPE probe labeling index ( ⁇ ) to evaluate the average probe density per sensor-bound vesicle. The measurements correlated well with ELISA analysis of vesicular EGFR expression.
- FIG. 3E Drug occupancy in EVs. We incubated EVs with increasing concentration of EGFR inhibitors (covalent: afatinib, osimertinib; and non-covalent: erlotinib) and employed the ExoSCOPE to measure relative EV drug occupancy ( ⁇ EV). A good agreement was observed between ⁇ EV and independent ⁇ cell analysis.
- FIG. 3D Quantification of EGFR expression in EVs.
- FIG.4A-4F Multiplexed ExoSCOPE for longitudinal drug analysis.
- FIG.4A Schematics of the multiplexed ExoSCOPE analysis.
- FIG.4B Time-dependent drug occupancy in EV and cell subpopulations.
- FIG.4C Longitudinal analysis with different targeted drugs.
- FIG. 4D Bland-Altman analysis. A good correlation was observed between ⁇ EV and the corresponding ⁇ cell, across multiple drugs and treatment conditions.
- FIG. 4F Correlation of ⁇ EV and GI50.
- H3255, PC9 vs. resistant (A431, H1975) cell lines. All measurements were performed in triplicate and the data are presented as mean ⁇ s.d. in FIGS.4B-4F.
- FIG. 5A-5E Clinical profiling of lung cancer patients.
- FIG. 5B Receiver operating characteristic curves of the ExoSCOPE analyses. The composite cancer signature, based on EGFR, EpCAM and MUC1, showed a high accuracy to diagnose lung cancer.
- FIG. 5C Longitudinal monitoring of targeted therapy. Plasma samples were collected from lung cancer patients at various time points: T 0 , before treatment (baseline); T1, 24 hours (day-1) after erlotinib treatment initiation; T2, 192 hours (day-8) after treatment initiation. Responder and non-responder status was clinically determined at the end of the treatment (day-21).
- FIG. 5D Multiplexed ExoSCOPE was performed to measure changes in EV drug occupancy ( ⁇ ) as well as changes in EV protein marker composition ( ⁇ M). Total drug concentration in plasma ( ⁇ D) was independently determined through conventional blood pharmacologic analysis (PK/PD).
- FIG. 5D Multiplexed ExoSCOPE for early time point (T1) assessments. Across different EV subpopulations, we measured respective longitudinal changes (T 1 with respect to T0) in EV drug occupancy ( ⁇ T1) and EV protein marker ( ⁇ MT1), and used the data to construct regression models for scoring drug occupancy changes (I ⁇ ) and marker composition changes (I M ), respectively. Corresponding changes in plasma drug concentration is denoted ⁇ D T1 .
- FIG. 5E ExoSCOPE differentiation of treatment outcome.
- FIG.6A-6E Multimodal characterization of vesicles derived from lung cancer cells.
- FIG. 6A Transmission electron micrograph (TEM) of EVs isolated from lung cancer cells (H3255). Inset shows a magnified view of a single vesicle.
- FIG.6B Western blotting analysis of EV and cell lysates (H3255).
- FIG.6C Unimodal size distribution of EVs derived from H3255 cell line, as determined by nanoparticle tracking analysis. The mean diameter was ⁇ 100 nm.
- FIG.6D Direct EV treatment.
- EVs isolated from untreated lung cancer cells were incubated with probe A3 (100 nM) in the absence (–) or presence (+) of drug (1 ⁇ M).
- probe A3 100 nM
- In-gel fluorescence analysis of the vesicle lysates after click reaction with tetrazine-TMR dye, confirmed probe A3’s ability for in situ labeling of vesicular EGFR and that the labeling is specific and afatinib-competitive (top).
- Western blotting analysis of EGFR and CD63 showed equal loading of the EV lysates (bottom).
- FIG. 6E Cell treatment. Lung cancer cells (H3255) were incubated with (+) or without (–) probe A3 (100 nM).
- FIG 7A-7B ExoSCOPE workflow and analysis.
- the ExoSCOPE leverages competitive target labeling by bio-orthogonal click probes to measure EV drug changes. To enable multiparametric measurements, we perform a series of operations, namely antibody functionalization on the sensor (baseline measurement), marker-induced EV binding (signal M), and probe-induced amplification (signal P), and measure the associated changes in transmitted light spectra for the corresponding molecular signals.
- vesicles are immuno-captured onto the functionalized sensors.
- probe labeling of sensor-bound vesicles, P
- TCO trans-cyclooctene
- HRP horseradish peroxidase
- EV drug occupancy is assessed through competitive probe labeling and enzymatic probe amplification. In comparison to vesicles with a high drug occupancy, EVs with a low drug occupancy are more extensively probe-labeled and amplified. The formation of localized, high- density optical deposits in these vesicles results in a red shift in the transmitted light spectrum, leading to an increased P signal.
- the ExoSCOPE measures marker-induced EV binding signal (M, promotional to the number of sensor- bound, antibody-captured vesicles) and probe-induced amplification signal (P, proportional to the total number of probes found within the captured vesicles).
- FIG. 8A and 8B ExoSCOPE spatial patterning through differential material functionalization. Schematics for spatial patterning of molecular reactions.
- FIG. 8A shows the process of in-ring functionalization, where the glass substrate of ExoSCOPE is first coated with APTES, and the capture antibodies are covalently attached to APTES using glutaraldehyde.
- FIG. 8B shows atop functionalization, where the gold layer is coated with carboxylated (HS-PEG-COOH) and methylated (HS-PEG-Me) thiol-PEG, and the capture antibodies are then coupled to the carboxylate group via EDC/NHC chemistry. Subsequently, both sensors can be applied through identical steps of EV capture and probe amplification, and the transmitted spectral shifts are measured accordingly.
- FIG. 9A-9D Optimization of the ExoSCOPE sensor.
- FIG. 9A Optimization of nanoring dimensions.
- FIG. 9B Photograph of the developed ExoSCOPE sensor.
- the sensor array consists of 3 ⁇ 7 sensing elements, patterned on a glass substrate (left). Each element comprises periodic lattices of gold nanorings. Large area scanning electron micrograph (SEM) showed uniformly fabricated nanorings (right).
- FIG. 9C Transmitted light spectra of the ExoSCOPE sensor. Increases in the refractive index induced a red shift in the transmission peak, towards the longer wavelength.
- FIG. 9D A linear correlation could be obtained between the changes in refractive index (RI) and the shifts in the transmitted peak wavelength.
- FIG. 10A-10C Evaluation of sensor variability.
- FIG. 10A Variability in nanoring fabrication. The nanoring resonators were patterned in a gold film to achieve the following optimized dimensions: 50 nm (thickness), 150 nm (inner ring diameter) and 350 (outer ring diameter). The results showed uniform fabrication and consistent optical performance across sensors. All characterization measurements were performed through SEM and AFM analysis.
- FIG. 10B Antibody functionalization. Across different functionalization experiments and antibodies used, antibody attachment coverage remained consistent.
- FIG. 10C Capturing efficiency with different antibodies and different EVs. EVs derived from different cell culture (A431 and H3255) could be effectively captured by anti-CD63 antibody.
- FIG. 11A illustrates synthesis of click probes. The synthesis began with a commercially available intermediate 1, which is commonly used for afatinib preparation. Firstly, substitution reaction was performed on 1 to incorporate a 3-carbon linker containing a Boc-protected amine. Next, the nitro group on 2 was reduced to amine and then functionalized with the Michael acceptor as afatinib.
- FIG.12A-12C show click chemistry of probes and reporters.
- FIG.12A illustrates ligating Azide (on probe A1) to dibenzocyclooctyne (DBCO) via strain-promoted alkyne-azide cycloaddition.
- FIG.12B and FIG.12C illustrate directly ligating TCO (A2, A3) to tetrazine through inverse electron-demand Diels–Alder reaction. All structures of the probes and their paired fluorescence reporters, DBCO-TMR, Tetrazine-TMR and Tetrazine-Cy5, as well as biotinylated reporter Tetrazine-Biotin, are illustrated. [29] FIG. 13A-13D. Target labeling by different click probes. Results of lysate labeling and live-cell labeling were compared . Click probes (100 nM) were used to label H3255 cells and revealed by in-gel fluorescence after click reaction with respective TMR dye reporter (FIG. 13A).
- FIG. 13B Click ELISA analysis was performed independently to quantify the EGFR labeling by probe A2 and A3 through the live-cell incubation (FIG. 13B). ELISA analysis was performed through protein immuno-capture with anti-EGFR antibody after click reaction with Tetrazine-Biotin reporter.
- FIG. 13C shows results of Coomassie stain of the gels in FIG.13 A, which showed equal loading of the lysates.
- the live-cell labeling samples were further analyzed through western blotting for EGFR and Actin and results were shown in FIG.13D.
- FIG. 14A-14D Performance evaluation of probe A3 in live cells.
- FIG. 14B Time-dependent labeling efficiency. Analysis of A3-labeled EGFR bands revealed time-dependent labeling, which reached 90% efficiency after 15 min incubation and maxima at 1 hr.
- FIG. 14C Competitive labeling with afatinib. H3255 cells were drug-treated with varying concentration of afatinib and labeled with probe A3 (100 nM). In- gel fluorescence revealed drug dose-dependent decrease in probe A3 labeling.
- FIG.15 Characterization of EVs and optical deposits. SEM images of control beads, beads with EVs and that after deposition of insoluble, optical products. For enzymatic deposition of optical products, probe-labeled EVs were captured onto antibody-functionalized polystyrene beads (through anti-CD63 capture). The bead-bound vesicles were then incubated with enzyme (HRP) and substrate (DAB) to catalyze the localized deposition of insoluble products. Distributional analysis showed an increase in mean particle size after the formation of insoluble deposits.
- HRP enzyme
- DAB substrate
- FIG. 16A-16C Theoretical comparison of nanoring and nanohole structures.
- FIG. 16A Schematics of the nanoring and nanohole structures. Both nanostructures have identical periodicity, thickness, and outer diameter.
- FIG. 16B Simulated transmission spectra when EVs (red dots) are captured at different locations on the nanoring or nanohole structures. With an equal amount of EV binding, the nanoring (in-ring) configuration experiences the the largest transmission spectral shift.
- FIG.16C The nanoring detection shows enhanced performance over the nanohole assays, especially when EVs are captured in the nanoring gap (in-ring), where the strongest electromagnetic field is located. All spectral shifts are determined from the transmitted peak wavelengths, relative to respective baseline measurements.
- FIG. 17A-17B Theoretical comparison of nanoring and nanohole structures.
- FIG.17A SEM characterization on the spatial distribution of bound EVs.
- the sensors were treated with different functionalization conditions. EVs were immuno-captured and probe-amplified.
- For the in- ring functionalization ⁇ 85% of the bound targets were located within the nanoring gap (in-ring).
- For the atop functionalization ⁇ 5% of the targets were captured in-ring and ⁇ 95% were bound to the gold surface (atop).
- FIG. 17B Experimental sensorgrams showed the superior performance of the in-ring functionalization.
- the optical spectra were determined after antibody conjugation (baseline), EV capture (EV marker signal) and probe amplification (probe signal), respectively.
- FIG.18A-18F The optical spectra were determined after antibody conjugation (baseline), EV capture (EV marker signal) and probe amplification (probe signal), respectively.
- FIG.18A Schematics of the ExoSCOPE platform and click ELISA.
- probe-labeled vesicles were antibody- captured onto the sensor surface, and incubated with HRP for enzymatic amplification.
- HRP HRP for enzymatic amplification.
- the bound HRP was used to convert soluble DAB substrate into insoluble deposits over labeled vesicles; this localized deposition of optical products results in an enhanced plasmonic signal (left).
- the click ELISA the bound HRP was used to generate chemiluminescence signal, through the conversion of Luminol substrate in solution (right).
- FIG. 18B ExoSCOPE analytical performance.
- FIG. 18C Probe labeling in plasma. EVs (derived from H3255 culture) were spiked into control plasma. Both the spiked sample and control plasma were labeled with probe A3, reacted with dye reporter and imaged through in-gel fluorescence.
- FIG.18D ExoSCOPE analysis of EVs spiked into plasma.
- EV marker signal (M) was measured through anti-CD63 capture antibody.
- Probe signal (P) was measure through A3 labeling and enzymatic amplification. Sample-matched control measurements were performed with IgG isotope control antibody. Plasma-spiked EV measurements demonstrated similar signals to that of pure EVs in PBS.
- FIG. 18E Western blotting analysis of EGFR expression in different cell lysates. EGFR expression levels were normalized to that of Actin.
- FIG. 18E Western blotting analysis of EGFR expression in different cell lysates. EGFR expression levels were normalized to that of Actin.
- FIG. 19A-19C Correlation of EV and cellular drug occupancy. Correlation of EV ( ⁇ EV ) and cellular ( ⁇ cell) drug occupancy by FIG. 19A Pearson analysis and FIG. 19B Bland-Altman analysis.
- FIGS. 19C-19D EVs and parent cells showed similar dose-dependent ⁇ EV and ⁇ cell curves against afatinib competition.
- EVs and cells bearing EGFR mutants H3255 with L858R mutation and PC9 with ex19del mutation
- FIG.20A-20B Flow cytometry analysis of cellular protein markers.
- FIG.20A Expression levels of putative cancer markers (EGFR, EpCAM, MUC1) and EV marker (CD63) in different cancer cell lines. All measurements were normalized against that of IgG isotype control antibodies.
- FIG. 20B Probe signal changes during drug treatment. A heterogeneous cell mixture was treated with erlotinib (1 ⁇ M) or vehicle (DMSO). Samples were obtained from the mixture at various time points during drug treatment and labeled with probe A3 (100 nM).
- FIG. 21A-21C Western blotting analysis of H3255 cells. The cells were treated with erlotinib (+, 1 ⁇ M) or vehicle (–, DMSO) for 6 hours. Receptor targets (EGFR and p-EGFR) and their downstream signaling proteins (p-Gab1, p-PLC ⁇ 1, p-Akt, p-Src) were quantified.
- FIG.21B EV concentrations in H3255 cell culture treated with erlotinib (1 ⁇ M), as determined by NTA.
- FIG.21C EGFR expression levels in the EV samples from FIG.21B, as measured by ELISA and normalized against CD63 expression. All measurements were performed in triplicate, and the data are displayed as mean ⁇ s.d. in FIGS.21B and 21C.
- FIG. 22A-22D Time-dependent changes in EV and cellular drug occupancy. Time- dependent changes in EV and cellular drug occupancy. (a-c) H3255 cells were treated with varied concentrations of FIG. 22A erlotinib, FIG. 22B afatinib or FIG.
- FIG. 22C osimertinib for 3 hours or 24 hours, respectively.
- the cells and secreted EVs were analyzed separately to evaluate their respective dose-dependent drug occupancy ( ⁇ cell and ⁇ EV).
- FIG. 22D Pearson analysis showed a good correlation of ⁇ EV and ⁇ cell at different doses and treatment durations, across different targeted drugs. All measurements were performed in triplicate, and the data are displayed as mean ⁇ s.d. in FIGS.22A–22C.
- FIG. 23A-23D Cellular growth inhibition by targeted inhibitors.
- 23A-23D shows proliferation inhibition of EGFR inhibitors on cancer cell lines known to express EGFR mutants L858R (H3255), ex19del (PC9), wild-type (A431) and L858R/T790M (H1975).
- Cells were treated with six EGFR inhibitors (afatinib, erlotinib, osimertinib, dacomitinib, WZ4002, CNX2006) for three days. Dose-dependent growth inhibition was determined by MTS assays. All measurements were performed in triplicate, and the data are displayed as mean ⁇ s.d.
- FIG. 23E Summary of GI 50 (nM), indicating that H3255 and PC9 cells are more sensitive to these drugs.
- FIG.24A-24F Other EV analyses to diagnose lung cancer.
- FIG. 24D ROC curve analysis of CD63 marker signals and vesicle counts showed poor diagnostic accuracy.
- FIG. 24E Correlation of ExoSCOPE marker signals with vesicle counts. Only CD63 analysis showed a good agreement to vesicle counts. Poor correlations were observed between respective cancer-marker signals and vesicle counts.
- FIG.24F Vesicle count distribution in clinical samples. No significant difference was observed between cancer vs. control samples, nor responder vs. non-responder samples. All measurements were performed in triplicate, and the data are displayed as mean ⁇ s.d. in FIGS.24A and 24F. (ns: not significant; Student’s t-test).
- FIG.25A-25C Longitudinal treatment monitoring by ExoSCOPE and conventional blood analysis. Scatter plots of longitudinal ExoSCOPE changes in FIG. 25A EV drug occupancy ( ⁇ ) and FIG. 25B protein marker ( ⁇ M).
- the present disclosure relates to a technology, termed extracellular vesicle analysis of small-molecule chemical occupancy and protein engagement (ExoSCOPE), which utilizes bio- orthogonal probe amplification and spatial patterning of molecular reactions within matched plasmonic nanoresonators for in situ analysis of EV drug dynamics.
- ExoSCOPE small-molecule chemical occupancy and protein engagement
- the technology is sensitive and informative. It detects delicate changes of drug binding with mutant proteins, provides multiparametric evaluation-drug occupancy and protein composition in molecular subpopulations of extracellular vesicles, and reveals real-time cellular changes of drug engagement and potency across different targeted drugs.
- the ExoSCOPE When applied for clinical cancer monitoring, through scant patient blood, the ExoSCOPE not only accurately classified disease status, but also rapidly distinguished targeted treatment outcomes, e.g., within 24 hours after treatment initiation.
- the present disclosure provides an analytical platform to leverage circulating extracellular vesicles for activity-based monitoring of tumor-specific drug-target interactions, directly in native blood samples.
- the technology termed extracellular vesicle analysis of drug occupancy and protein engagement (ExoSCOPE), utilizes bio-orthogonal probe amplification and spatial patterning of molecular reactions within matched plasmonic nanoring resonators, to achieve in situ analysis of EV drug dynamics.
- the technology is sensitive and informative.
- the ExoSCOPE not only accurately classified disease status, but also rapidly distinguished targeted treatment outcomes, e.g., within 24 hours after treatment initiation.
- the methods and compositions disclosed herein leverage bio-orthogonal probe amplification, spatial patterning of molecular reactions within matched plasmonic nanoring resonators and in situ enzymatic conversion of optical product for localized signal amplification for signal amplification.
- the platform thus enables 1) high sensitivity;
- the platform showed a limit of detection (LOD) of ⁇ 1,000 probe-labeled extracellular vesicles, which is 104-fold better than that of ELISA-based assay.2) measurement of time-dependent drug dynamics in distinct subpopulations of secreted vesicles.3) examine serial blood samples of cancer patients undergoing targeted therapy and not only accurately classify disease status, but also effectively distinguish treatment outcomes.
- the technology also employs spatially-optimized plasmonic nanoresonators (e.g., nanoring resonators) and in situ enzymatic conversion of localized optical product for signal amplification and molecular co-localization to enable highly sensitive, multiplexed population analysis.
- Additional benefits provided by the technology disclosed herein include but are not limited to the following.
- the ExoSCOPE classification based on vesicular drug dynamics was accurate and correlated well with clinical patient survival data, indicating the effectiveness of the technology for early monitoring of targeted treatment outcomes.
- the methods and compositions disclosed herein enable inexpensive, direct, non-invasive and quantitative detection of lung cancers: Current clinical evaluation of targeted cancer therapies in solid tumors relies primarily on tumor volumetric imaging, which is delayed and insensitive to drug molecular interactions and mechanisms. Therefore, we develop a dedicated analytical platform to leverage circulating extracellular vesicles for activity-based monitoring of tumor-specific drug- target interactions, directly in native blood samples.
- the invention could accurately detected cancer patients, and further revealed drug occupancy signatures to distinguish treatment efficacy.
- the methods and compositions disclosed herein enable early monitoring of targeted therapy outcomes: Clinically, responder and non-responder status was determined at the end of the treatment (day-21) by tumor volumetric imaging. Through multiplexed analysis on time-dependent changes in EV drug occupancy ( ⁇ ), this invention could effectively distinguish responders from non-responders (P ⁇ 0.0005) undergoing targeted treatment of EGFR inhibitor. The difference could be observed as early as in 24 hours after treatment initiation, using only 5 ⁇ L of native plasma samples [51] Various features related to the ExoSCOPE technology are set forth below and further explained in detail.
- biomarker as used herein is understood to be an agent or entity whose presence or level correlates with an event of interest.
- the biomarker may be a cell, a protein, nucleic acid, peptide, glycopeptide, an extracellular vesicle, or combinations thereof.
- the biomarker is an EGFR protein whose presence or level indicates whether a subject suffers from, or is at risk of developing lung cancer.
- cancer marker refers to a biomarker that is preferentially expressed in cancer than a normal tissue.
- subject means any animal, including any vertebrate or mammal, and, in particular, a human, and can also be referred to, e.g., as an individual or patient.
- antibody includes, but is not limited to, synthetic antibodies, monoclonal antibodies, recombinantly produced antibodies, multispecific antibodies (including bi-specific antibodies), human antibodies, humanized antibodies, chimeric antibodies, single-chain Fvs (scFv), Fab fragments, F(ab′) fragments, disulfide-linked Fvs (sdFv) (including bi-specific sdFvs), and anti- idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.
- the antibodies provided herein may be monospecific, bispecific, trispecific or of greater multi-specificity.
- Multispecific antibodies may be specific for different epitopes of a polypeptide or may be specific for both a polypeptide as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material.
- protein and “polypeptide” are used interchangeably and refer to any polymer of amino acids (dipeptide or greater) linked through peptide bonds or modified peptide bonds. Polypeptides of less than about 10-20 amino acid residues are commonly referred to as "peptides.”
- the polypeptides of the invention may comprise non-peptidic components, such as carbohydrate groups.
- Carbohydrates and other non-peptidic substituents may be added to a polypeptide by the cell in which the polypeptide is produced and will vary with the type of cell.
- Polypeptides are defined herein, in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present, nonetheless.
- sample refers to any sample comprising or being tested for the presence of a target of a drug of interest.
- Such a sample includes samples derived from or containing cells, organisms (bacteria, viruses), lysed cells or organisms, cellular extracts, nuclear extracts, components of cells or organisms, extracellular fluid, media in which cells or organisms are cultured in vitro, blood, plasma, serum, gastrointestinal secretions, urine, ascites, homogenates of tissues or tumors, synovial fluid, feces, saliva, sputum, cyst fluid, amniotic fluid, cerebrospinal fluid, peritoneal fluid, lung lavage fluid, semen, lymphatic fluid, tears, pleural fluid, nipple aspirates, breast milk, external sections of the skin, respiratory, intestinal, and genitourinary tracts, and prostatic fluid.
- a sample can be a viral or bacterial sample, a sample obtained from an environmental source, such as a body of polluted water, an air sample, or a soil sample, as well as a food industry sample.
- a sample can be a biological sample which refers to the fact that it is derived or obtained from a living organism. The organism can be in vivo (e.g. a whole organism) or can be in vitro (e.g., cells or organs grown in culture).
- a "biological sample” also refers to a cell or population of cells or a quantity of tissue or fluid from a subject.
- biological sample can also refer to cells or tissue analyzed in vivo, i.e., without removal from the subject.
- a biological sample will contain cells from a subject, but the term can also refer to non-cellular biological material, such as non-cellular fractions of blood, saliva, or urine.
- the biological sample may be from a resection, bronchoscopic biopsy, or core needle biopsy of a primary, secondary or metastatic tumor, or a cellblock from pleural fluid.
- fine needle aspirate biological samples are also useful.
- a biological sample is primary ascites cells.
- Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues.
- a biological sample can be provided by removing a sample of cells from subject, but can also be accomplished by using previously isolated cells or cellular extracts (e.g. isolated by another person, at another time, and/or for another purpose). Archival tissues, such as those having treatment or outcome history may also be used. Biological samples include, but are not limited to, tissue biopsies, scrapes (e.g. buccal scrapes), whole blood, plasma, serum, urine, saliva, cell culture, or cerebrospinal fluid. The samples analyzed by the compositions and methods described herein may have been processed for purification or enrichment of extracellular vesicles contained therein. In one embodiment, the sample is blood.
- resist refers to both a thin layer used to transfer an image or pattern to a substrate which it is deposited upon.
- a resist can be patterned via lithography to form a (sub)micrometer- scale, temporary mask that protects selected areas of the underlying substrate during subsequent processing steps, typically etching.
- the material used to prepare the thin layer (typically a viscous solution) is also encompassed by the term resist.
- Resists are generally mixtures of a polymer or its precursor and other small molecules (e.g. photoacid generators) that have been specially formulated for a given lithography technology.
- EVs Extracellular vesicles
- Extracellular vesicles are nanoscale membrane vesicles actively secreted by a variety of mammalian cells, and most notably by rapidly dividing cancer cells (Refs. 10 and 11).
- vesicles abound in blood, play important roles in mediating intercellular communication (Refs. 12, 13), and contain a trove of reflective molecular contents inherited from the parent cells (e.g., proteins (Refs. 14, 15), nucleic acids (Refs. 16, 17), lipids as well as various modifications (Refs.18, 19)). These vesicles are shed by eukaryotic cells, or budded off of the plasma membrane, to the exterior of the cell. These membrane vesicles are heterogeneous in size with diameters ranging from about 10 nm to about 5000 nm.
- the small vesicles (approximately 10 to l000 nm, preferably 30 to 100 nm in diameter) that are released by exocytosis of intracellular multivesicular bodies or outward budding of plasma membrane are referred to in the art as "extracellular vesicles”. See, Cocucci et a., (2015). The methods and compositions described herein are equally applicable for other vesicles of all sizes. [64]
- the application provides useful methods and compositions related to technology, referred to herein as ExoSCOPE, which analyzes the drug-bound proteins on EVs to molecularly characterize specific drug-target interactions, even of solid tumors.
- a plasma sample from a patient is used directly for the ExoSCOPE analysis, without the need for isolating EV’s from the rest of the plasma sample, as described below.
- EVs can be isolated from in vitro cell culture, e.g., tumor cells lines, as described below.
- EVs can be isolated from a bodily fluid (e.g., a blood sample) or a sample prepared from a tissue (e.g., a tumor biopsy) from a patient by differential centrifugation. This method typically employs a series of centrifugation steps with increasing centrifugal force to separate the extracellular vesicles from cells, cell debris and other larger cellular particles.
- the blood sample can be first centrifuged at 10,000g to remove any debris and/or apoptotic bodies and subsequently at 100,000g to precipitate EVs.
- the extracellular vesicles are then collected, washed and resuspended in suitable buffer, e.g., PBS. If needed, the extracellular vesicles so prepared can be stored at -80 oC for future usage.
- extracellular vesicles can be isolated using a size exclusion chromatography. Suitable size exclusion chromatography is commercially available, for example, sepharose 2B columns, available from Sigma Aldrich (St. Louis, MO). The columns are prepared according to manufacturer’s instructions.
- EVs prepared as above can be confirmed based on the presence of EV molecular and biochemical markers, using methods well known in the art.
- the presence of extracellular vesicles can be confirmed using flow cytometry to analyze markers associated with EVs, e.g., CD63 and CD81.
- the concentration and size distribution of the EVs can be analyzed using the devices commercially available, for example, the nanoparticle tracking analysis (NTA) system (Nanosight, NS300).
- NTA nanoparticle tracking analysis
- the presence of extracellular vesicles can be confirmed using Western blots to detect EV proteins described above.
- size and morphology of the extracellular vesicles can be confirmed using methods such as flow cytometry and transmission electron microscopy.
- the EVs obtained from patient samples are captured on a sensor.
- the interaction of drug and its target on the EVs are analyzed using bio- orthogonal probes that are competitive with the drug in binding to its target, as further discussed below.
- BIO-ORTHOGONAL PROBE [67] Aspects of the invention involve bio-orthogonal probes that can be used to label target proteins.
- a bio-orthogonal probe refers to a molecule that binds to a target protein (e.g., the EGFR protein) and comprises a chemically tractable tag enable label to enable label visualization or in situ enzymatic amplification.
- the probes were developed for competitive, in situ target labeling in whole extracellular vesicles; this probe labeling can be enzymatically amplified to reflect EV drug occupancy.
- the probes are used for rapid, sensitive and specific detection of EGFR proteins and the EGFR drug-target interactions in various settings (cell lysate, live cells, extracellular vesicles and plasma samples).
- a bio-orthogonal probe disclosed herein typically comprise a core structure for competitive binding with the drug to the target on the EVs, a chemical the tractable tag, and a linker connecting the chemical the tractable tag and the core structure.
- the bio-orthogonal probes are designed to be able to compete with a drug of interest in binding to its target.
- the bio-orthogonal probe comprises a core structure that closely resembles the drug such that it is capable of competing with the drug in binding its cognate site in the target.
- the bio-orthogonal probe may bind to the same site or near the same site on the target as the drug.
- the site on the target that the drug binds are referred to as the cognate site of the drug.
- the bio-orthogonal probe confers specific covalent binding to cognate site of the drug on the target and thus blocks the drug from accessing the cognate site.
- the bio-orthogonal probe does not confer specific covalent binding to cognate site of the drug on the target, but blocks the drug from accessing its cognate site through other means, e.g., steric hindrance.
- Methods for designing probes having the core structure of the drug of a known structure so that it can compete with the drug are well known.
- the molecular interaction between the drug and the target are analyzed and probes are then designed based on the three dimensional configurations. For example, the cognate site of the drug on the target can be identified by from the crystal structure of the drug in complex with the target.
- bio-orthogonal probes that can bind to the cognate site on the target can also be designed by using computer modeling, for example covalent docking using flexible side chain method at the cognate site of the target.
- Software packages for performing such modeling are well known and available, for example, AutoDock Vina, visualized by PyMOL (version 2.3.2).
- the target is EGFR and the drug is an EGFR inhibitor.
- EGFR inhibitors include small-molecule tyrosine kinase inhibitors, such as gefitinib, erlotinib, afatinib, osimertinib, and icotinib, dacomitinib, CNX2006, and WZ4002.
- Gefitinib, erlotinib, and icotinib bind reversibly to EGFR and thereby inhibit both the mutant and the wild type EGFR.
- Afatinib and Osimertinib bind covalently and irreversibly blocks EGFR signaling.
- the bio-orthogonal probe is capable of competing with afatinib in binding to the cognate site in EGFR.
- the cognate site is the adenosine triphosphate (ATP) binding pocket of the tyrosine kinase domain of EGFR, a well-known druggable target. See, Kumar et al., (2008), the relevant disclosure is herein incorporated by reference. It is a catalytic domain of protein kinase that relies on ATP as substrate, and the binding of drug will compete with ATP and hence inhibit kinase activity
- the cognate site of afatinib on EGFR comprise Cys797.
- Various probes can be designed to compete with afatinib to bind to EGFR at cognate site.
- the bio-orthogonal probe is synthesized based on the core structure of afatinib (BIBW2992) (Li et al. (2008)) to confer specific covalent binding to the EGFR kinase site. Exemplary procedures used to produce a bio orthogonal probe is described in FIG. 11 and also Example 8.
- the bio-orthogonal probe that competes with afatinib has a structure of formula I below. [73]
- R contains a chemically tractable tag and a three-carbon linker.
- R is selected from the group consisting of [74]
- the probe comprises or consists of the structure of A1: [75]
- the probe comprises or consists of A2: [76]
- the probe comprises or consists of A3: Chemically tractable tag and signaling amplification [77]
- the bio-orthogonal probe further comprises a chemically tractable tag to enable visualization and/or in situ enzymatic amplification of the signal resulted from binding of the bio- orthogonal probe to the EVs.
- the chemical tractable tag used herein can be any molecule that is detectable.
- the chemical tractable tag is one that can participate in a chemical reaction to produce an insoluble optical product that can be detected, and the detected signal corresponds to the binding of the click probe to the target.
- the chemically tractable tag is ligated to a reporter (e.g., Cy5) through a click chemistry.
- a reporter e.g., Cy5
- a bio-orthogonal probe comprising the chemically tractable tag that can be ligated to a reporter through click chemistry is referred to as a click probe in this disclosure.
- the click chemistry is a rapid copper-free bio-orthogonal ligation (also known as copper-free click chemistry or copper free click reaction) (Jewett, J. C. & Bertozzi, C.
- the chemical tractable tag is able to participate in a copper-free click chemical reaction.
- the chemical tractable tags include an azide, and a trans-cyclooctene (TCO). (Refs.24 and 25).
- the R group of a probe according to formula I comprises an azide (for example, probe A1), which can be conjugated to dibernzocyclooctyne (DBCO).
- DBCO dibernzocyclooctyne
- the click probes having this structure can be used to recruit a DBCO-conjugated reporter, e.g., a DBCO-conjugated Cy5.
- the R group comprises a trans-cyclooctene (TCO), which can be directly conjugated to a tetrazine.
- TCO trans-cyclooctene
- the click probes having this structure can be used to recruit a tetrazine-conjugated reporter.
- Various probes and the respective reporters that they ligate to are shown in FIG.12.
- Cy5 any other reporter that is capable of producing a detectable signal can be used to ligate to the chemically tractable tag, for example, those produce fluorescent, such as, include rhodamine, tetramethylrhodamine (TMR, TMARA) or luminescent signals.
- the bio-orthogonal probe further comprises a linker (e.g., a carbon linker) connecting the chemically tractable tag and the rest of the probe (e.g., the core structure).
- a linker e.g., a carbon linker
- the R group in formula (I) comprises or consists of a carbon linker and one or more chemical tractable tags.
- the carbon linker used in the probe is short in length so that it does not interfere with the biological properties of the probe.
- the carbon linker has no more than 10 carbons. In some embodiments, the carbon linker has 2-6 carbons, e.g., 2-5 carbons, or about 3 carbons.
- Signal amplification the chemically tractable tag can recruit a signal amplifying moiety comprising an enzyme, and enzyme can induce the formation of an insoluble aggregate on the surface on the sensor chip, e.g., by catalyzing in situ conversion of a soluble substrate to form a local insoluble deposits on the probe-bound vesicles (FIG. 7a). These high-density optical deposits, formed in low-drug-occupancy EVs, lead to plasmonic signal enhancement and a red shift in the resultant transmission optical spectrum.
- In situ amplification increases the sensitivity of the sensor chip by resulting in a greater change in transmission wavelength (spectral shift) or change in transmission intensity when a second recognition molecule binds to an analyte on the surface of the sensor chip.
- the enzyme may be horse radish peroxidase (HRP), alkaline phosphatase, glucose oxidase, ⁇ -lactamase or ⁇ -galactosidase or an enzymatic fragment thereof.
- the enzyme is horse radish peroxidase.
- the first biorecognition molecule is fused to the signal amplification moiety.
- the first biorecognition molecule may be an antibody that is covalently fused to a horse radish peroxidase enzyme that is covalently linked to the antibody using techniques that are well known in the art.
- the method may further comprise contacting the enzyme with an enzyme substrate.
- the enzyme substrate may be one that could form an insoluble product in the presence of enzymes or upon enzymatic action.
- HRP horse radish peroxidase
- formulations such as 3-amino-9- ethylcarbazole, 3,3’,5,5’-Tetramethylbenzidine or Chloronaphthol, 4-chloro-1-naphthol can be used.
- the enzyme substrate is 3,3'-diaminobenzidine tetrahydrochloride.
- the chemically tractable tag recruits the signal amplifying moiety through a click chemistry, e.g., a copper-free click chemical reaction.
- a click probe comprise azide as the chemically tractable tag, which can be readily ligated to an enzyme to that is conjugated to dibernzocyclooctyne (DBCO).
- the click probes having this structure can be used to recruit a DBCO-conjugated enzyme, e.g., a DBCO-conjugated HRP.
- a click probe comprises a trans-cyclooctene (TCO) as the chemically tractable tag, which can be directly conjugated to a tetrazine via click chemistry.
- Click probes having this structure can be used to recruit a tetrazine-conjugated enzyme, e.g., a tetrazine-conjugated HRP. Evaluating the properties of the bio-orthogonal probes [85] The bio-orthogonal probe competes with the drug in binding to the target on the EVs.
- the ability of the probe to compete with the drug can be determined using a competitive binding assay.
- a competitive binding assay is set up in which the bio-orthogonal probe incubated with cells or EVs expressing the target, e.g., EGFR, in the presence of varying concentrations of the drug (e.g., afatinib).
- a drug dose-dependent decrease in the probe labeling of the target indicates the probe competes with the drug (i.e., the probe is competitive to the drug in binding the target).
- the IC 50 of the drug from the competitive binding assay (i.e., the concentration of the drug used which corresponds to 50% of signal from probe’s labeling of the target in the absence of the drug) is in the range of 0.5 nM to 10 nM, e.g., the 1.0 nM to 5 nM, or about 1.4 to 1.6 nM.
- Assays for conducting such competitive binding include, but are not limited to, in-gel fluorescence, flow cytometry, and click ELISA.
- One illustrative experiment in Fig.2c and 2e showed that probe A3 competed with afatinib and the IC 50 of the afatinib was 1.4 to 1.6 nM.
- a bio-orthogonal probe disclosed herein possess substantially similar functional activity as the drug that it competes with.
- the drug has a role of inhibiting proliferation (“anti-proliferation”) of cancer cells
- the bio-orthogonal probe and the drug can be evaluated in a proliferation assay of the target cell lines, and the inhibition function on proliferation can be evaluated.
- the anti-proliferation function is measured by a GI 50 .
- GI 50 measures the anti-proliferation function of the drug or the bio-orthogonal probe.
- GI50 equals to the concentration of the drug or probe used to cause 50% inhibition of proliferation. A lower GI50 indicates a higher potency, i.e., a higher anti-proliferation activity. In some embodiments the GI 50 of the bio-orthogonal probes is in a range of 50%-500% of the GI 50 of the drug itself, e.g., 60%-300%, 100%-400%, or 100%-300%. As compared to A2, A3 showed enhanced anti-proliferation activity on human lung cancer cells H3255. See FIG.2B. And as compared to A1 and A2, A3 demonstrated the highest signal-to-noise ratio in terms of target (e.g., EGFR) labeling. See FIG. 2C and Example 3.
- target e.g., EGFR
- the bio-orthogonal probe is also selected based on its lipophilicity. Lipophilicity affects the solubility, permeability, potency, selectivity, absorption, distribution of the probe. Typically, a higher lipophilicity is associated with higher permeability but lower solubility. It is desirable to have probes having an optimal lipophilicity such that it can enter the EVs to bind the target with high potency.
- probes that have properties similar to that of the drug (e.g., afatinib) to achieve competition in binding to the target (e.g., EGFR).
- Lipophilicity of the probes can be evaluated by a distribution coefficient, cLogD (also referred to as LogD). A higher value of cLogD indicates a higher lipophilicity. Methods to measure the distribution coefficient are well known, for example, as described in Csizmadia F, et al. (1997).
- the probe has a cLogD that in range of 60% to 400% of the value of the drug it competes with in binding the target on the EVs under the same assay conditions, for example, 70% to 300%, 80% to 200%, 90% to 180%.
- the same conditions include the same pH, e.g., pH 7.4.
- A3 showed improved lipophilicity that is closer to that of the drug, Afatinib. See FIG. 2B.
- A3 demonstrated the highest signal- to-noise ratio. See FIG.2C and Example 3 below.
- A1-A3 compete with afatinib in binding to EGFR.
- synthesis of the click probes can begin with an intermediate product that is used to produce the drug of interest, e.g., Afatinib.
- Carbon linkers containing a Boc-protected amine is incorporated which is followed by removing the Boc protection group and the resulting amino group can be converted to azide or different trans-cyclooctene TCO building blocks to produce click probes.
- NMR analysis can be performed during each step of synthesis to confirm the formation of the product.
- FIG. 11 show an illustrative example of synthesis of click probes that are competitive to afatinib.
- the synthesis began with a commercially available intermediate 1, which is commonly used for afatinib preparation. Firstly, substitution reaction was performed on 1 to incorporate a 3-carbon linker containing a Boc-protected amine. Next, the nitro group on 2 was reduced to amine and then functionalized with the Michael acceptor as afatinib. Finally, the Boc protection group on 3 was removed and the resulting amino group was either converted to azide (A1) or coupled with different trans-cyclooctene TCO building blocks to yield the click probes (A2, A3) accordingly.
- the methods and compositions of the disclosure use a sensor to detect interactions among the bio -orthogonal probe, EVs, and the capture agent on the sensor.
- the sensor is a plasmonic sensor, which generates a plasmonic resonance and/or plasmonic coupling when illuminated by an optical source. Plasmonic resonance may be influenced by factors such as materials and geometric features, causing an enhanced electromagnetic field distribution near the dielectric interface.
- the senor comprises at least a conductive layer that is deposited above a substrate layer.
- the conductive layer can be any metal layer, for example, gold, copper, titanium, aluminum, and chromium.
- the substrate ⁇ Aizpurua, J. et al. Optical properties of gold nanorings.
- the conductive layer comprises nanostructures that are patterned to form nanogaps (nanovoids) among them.
- the nanogaps are of appropriate sizes such that they provide spaces to capture optical energy and produce plasmonic resonance and/or plasmonic coupling.
- These nanostructures are also referred to as nanoresonators or plasmonic nanoresonators.
- the average size of the nanogaps are in the range of 20 to 500 nm, for example, 20- 200 nm, 50 to 450 nm, 100 to 400 nm, or 150 nm to 250 nm, or about 200 nm.
- the thickness of the nanostructures are in the range of 20 nm-200 nm, 20 nm-100nm, 30 nm -90 nm, or about 50 nm.
- FIG. 10 illustrates the thickness, outer diameter, and the inner diameter of an exemplary nanostructure of the sensor. [93]
- the nanogaps in the sensor are of uniform size.
- the nanogap structures are patterned on the substrate to form a periodic lattice.
- periodic lattice refers to a network of nanostructures (e.g., nanorings) arranged in a uniform and periodic pattern.
- periodicity refers to the recurrence or repetition of nanostructures at regular intervals by their positioning on the sensor chip. The term “periodic” thus refers to the regular predefined pattern of nanostructures with respect to each other.
- the regular periodicity among the nanorings may allow the tight control of the resonance wavelength and penetration of the evanescent wave.
- the nanostructures have a periodicity of about 250 nm to about 650 nm.
- the nanostructures have a periodicity selected from the group consisting of 250 nm, 260 nm, 270 nm, 280 nm, 290 nm, 300 nm, 310 nm, 320 nm, 330 nm, 340 nm, 350 nm, 360 nm, 370 nm, 380 nm, 390 nm, 400 nm, 410 nm, 420 nm, 430 nm, 440 nm, 450 nm, 460 nm, 470 nm, 480 nm, 490 nm, 500 nm, 510 nm, 520 nm, 530 nm, 540 nm, 550 nm, 560 nm, 570 nm, 580 nm, 590 nm, 600 nm, 610 nm, 620 nm, 630 nm, 640 nm and 650
- the nanostructures have a periodicity of 450 nm.
- the nanostructures comprised in the conductive layer are nanorings.
- the conductive layer is a gold layer and the nanorings so formed are referred to as gold nanorings.
- Each nanoring comprises a nanoring gap, which is defined by an outer circular shape and an inner circular shape and the size of the nanoring gap equals to the half of the difference between the outer circle diameter and the inner circle diameter.
- the outer circular shape has an outer diameter in a range from 200 nm to 500 nm, and /or the inner circular shape has a inner diameter in a range from 30 nm to 250 nm.
- the thickness of the nanorings is in the range of 20 nm -200 nm, e.g., 20 nm-100 nm, 30 nm -90 nm, or about 50 nm.
- FIG. 10 illustrates the thickness, outer diameter, and the inner diameter of an exemplary nanostructure of the sensor.
- a sensor comprising nanoring resonators patterned in a gold film with dimensions of 50 nm (thickness), 150 nm (in ring diameter) and 350 nm (outer ring diameter) showed uniform fabrication and consistent optical performance across sensors.
- the sensor used in this application comprises an array of sensing elements, and this type of sensor is also referred to as a sensor array in this disclosure.
- each sensing element comprises a spatially-optimized nanorings.
- FIG. 16 a periodic lattice of nanorings showed higher signal amplification as compared to nanoholes, suggesting that sensors using nanoring resonators are more sensitive in signal detection.
- Field simulation experiments showed that the electromagnetic fields within the nanoring gap (“in-ring”) of the nanoring structures, were stronger than as compared to that on the sensor surface (“atop”) (Fig.3B, left). These results show that the sensor comprising periodic lattices of gold nanorings have improved spatial control for signal amplification.
- a click probe is designed such that it can be used for competitive, in situ target labeling in whole extracellular vesicles; this probe labeling can be enzymatically amplified to reflect EV drug occupancy, as further disclosed herein.
- the senor comprise an array of sensing elements different sensoring elements are in ring functionalized with different capture agents, such that the sensor can be used for multiplex detection, as further discussed below.
- Sensor fabrication a microarray chip containing a large number of sensing elements can be fabricated for high-throughput, multiplexed analysis, as well as parallel measurements of multiple biomarkers.
- the chip is a microarray nanoring sensor chips with an improved and coupled optical performance is robust Methods for manufacturing arrays having sensing elements are described in, for example, Xin et al. (2016), entire content of which is herein incorporated by reference.
- the sensor may be fabricated using one or more of the following steps.
- a glass substrate can be coated with PMMA 495k, and additional layers of Espacer to improve substrate conductivity.
- lithography EBL, Joel 6300FS
- An adhesion layer may also deposited onto the substrate that bear the nanoring pattern.
- a lift-off process in solvent stripper is performed.
- the dimensions of the naorings can be characterized by microscopy, e.g., scanning electron microscopy and/or atomic force microscopy.
- the nanorings of the sensor then can be functionalized with specific molecules for detection of certain molecules on the EVs.
- Channel assembly [100] Standard lithography can be used to fabricate a multichannel flow cell that comprises channels for delivering reagents to the sensor.
- One exemplary procedure of channel assembly is shown in Example 1.
- a SU-8 negative resist is spin-coated on a Si wafer and then baked at high temperature briefly, for example at 65 C and 95 C for 1 and 6 min. In some cases, after UV light exposure, the resist is baked again before being developed under agitation. The developed wafer can then be rinsed and dried.
- the resist is then chemically treated by e.g., trichlorosilane vapor inside a desiccator for 15 min, and treated by polydimethylsiloxane polymer (PDMS) and cross-linker that are mixed at a suitable ratio (e.g., a ratio of 10:1).
- PDMS polydimethylsiloxane polymer
- the treated SU-8 mold is then cured at a high temperature (e.g., in an oven at 75 °C for 30 min).
- the PDMS layer can be cut from the SU-8 mold and assembled onto the ExoSCOPE sensor.
- the channels are processed to have inlets and outlets with dimensions suitable for sample processing.
- a light source is provided to illuminate the ExoSCOPE sensor.
- Transmitted light is then collected and fed to a detector (e.g., a spectrometer) and the intensity of the light can be recorded in counts against wavelength.
- a detector e.g., a spectrometer
- the spectral peaks of the transmitted light can be analyzed using a software package suitable for this purpose, for example, a custom-built R program by fitting the transmission peak using local regression method.
- Microfluidic system Any one of the assay workflows disclosed herein can be implemented in a microfluidic system.
- the microfluidic system comprises a flow cell housing the sensor array comprising a plurality of sensing elements.
- the system may further comprise microfluidic channels for introducing samples into the sensor array.
- the system provides a light source to illuminate the sensor array.
- the microarray chips are pre-functionalized with capture agents (e.g., antibodies against cancer markers) to enable rapid and sensitive readouts, without requiring extensive sample processing and is thus suitable for targeted clinical measurements.
- capture agents e.g., antibodies against cancer markers
- the microfluidic implementation disclosed herein facilitates parallel workflow and enables small volume of samples to be used for detection with the developed platform. Detecting binding of EVs and probes to the sensor [105]
- the detection of "binding" of the EVs or the click probe to the captured agent on the surface of a sensor may be via a spectral shift in terms (change in transmission wavelength) or a change in transmission intensity at a fixed wavelength. For example, an EV that is captured on a surface of a sensor chip will have an initial reference wavelength.
- the associated transmission spectrum may shift to a longer wavelength.
- the change in transmission resonance wavelength (or spectral shift ( ⁇ ⁇ )) or change in transmission intensity at a fixed wavelength in a sample may be compared to the change that is observed in a control sample. This may be used to, for example, determine whether there is increased binding of a bio-orthogonal probe to the captured EV.
- the "increased binding of the bio-orthogonal probe" in a sample as compared to a control sample may be determined by comparing the change in spectral shift, or a change in transmission intensity at a fixed wavelength, between the sample and the control sample upon binding of the second recognition molecule.
- An increased change in spectral shift or change in transmission intensity may indicate that there is an increased binding of the second recognition molecule to the analyte.
- the increased change in spectral shift or transmission intensity may refer to a 1.2-fold or greater increase between the subject and the control subject.
- the term may also refer to an increase that is selected from a group consisting of 1.1 fold, 1.3 fold, 1.4 fold, 1.5 fold, 1.6 fold, 1.7 fold, 1.8 fold, 1.9 fold, 2 fold, 3 fold, 4 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 11 fold, 12 fold, 13 fold, 14 fold, 15 fold, 16 fold, 17 fold, 18 fold, 19 fold, 20 fold, 21 fold, 22 fold, 23 fold, 24 fold, 25 fold, 26 fold, 27 fold, 28 fold, 29 fold, 30 fold, 31 fold, 32 fold, 33 fold, 34 fold, 35 fold, 36 fold, 37 fold, 38 fold, 39 fold, 40 fold, 41 fold, 42 fold, 43 fold, 44 fold, 45 fold, 46 fold, 47 fold, 48 fold, 49 fold, 50 fold, 51 fold, 52 fold, 53 fold, 54 fold, 55 fold, 56 fold, 57 fold, 58 fold, 59 fold, 60 fold, 61 fold, 62 fold, 63 fold, 64 fold, 65 fold, 66 fold, 67 fold
- ExoSCOPE represents an assay format and system supporting the assay used in extracellular vesicle monitoring of drug occupancy and protein expression. ExoSCOPE utilizes bio- orthogonal probe amplification and spatial patterning of molecular reactions within matched plasmonic nanoring resonators to achieve in situ analysis of EV drug dynamics. [110] In some embodiments, ExoSCOPE is used to evaluate drug occupancy of a subject who has been treated with a drug. EVs from a biological sample (e.g., a plasma sample) from patients who have been treated with the drug (e.g., an EGFR inhibitor) are collected and immobilized onto the sensor that have been functionalized with a capture agent that can bind to the EVs.
- a biological sample e.g., a plasma sample
- the drug e.g., an EGFR inhibitor
- the capture agent is an antibody. In some embodiments, the capture agent is anti- CD63, CD81, or CD9. In some embodiments, the capture agent is an antibody against a cancer marker, e.g., HER2, MUC1, EpCAM and EGFR.
- a cancer marker e.g., HER2, MUC1, EpCAM and EGFR.
- At least 70%, at least 80%, at least 85%, at least 90%, or at least 95% of the capture agent molecules are immobilized on the substrate in the nanoring, referred to as “in – ring functionalization”.
- FIG. 3B left field simulations showed that the enhanced electromagnetic fields were located within the nanoring gap (“in-ring”) as compared to that on the sensor’s conductive surface (“atop”) (FIG. 3B, left).
- FIG. 17 as compared to atop functionalization, in ring functionalization showed superior performance.
- the nanoring gaps of each sensing element are in ring functionalized with molecules of a capture agent.
- the senor comprises multiple sensing elements and at least one sensing element is in ring functionalized with a capture agent that is different from another sensing element.
- the capture agent is an antibody.
- the antibody may, for example, be an antibody that recognizes a pan-EV biomarker or a marker that is associated or bound to an EV.
- the antibody may be an antibody that is specific to CD63, LAMP-1, Alix, HSP90, Flotillin 1, TSG101, CD9 or CD81, which are abundant and characteristic in EVs.
- the antibody may also be specific to a cancer marker such as HER2, EGFR, EpCAM, and MUC1.
- the capture agent may be immobilized on the sensor using techniques that are well known in the art.
- the capture agent may be adsorbed onto the surface.
- the surface may be coated with a layer of streptavidin or avidin prior to immobilization of the capture agent.
- the capture agent molecule may be biotinylated and immobilized onto the surface via streptavidin- biotin conjugation.
- the surface may be treated with polyethylene glycol (PEG) molecules.
- the surface may be treated with an active (carboxylated) thiol-PEG.
- the surface may then be activated through carbodiimide crosslinking in a mixture of excess NHS/EDC dissolved in MES buffer and conjugated with the capture agent molecule.
- the surface may be treated with a mixture of polyethylene glycol (PEG) containing long active (carboxylated) thiol-PEG and short inactive methylated thiol-PEG.
- PEG polyethylene glycol
- the ratio of long active (carboxylated) thiol-PEG to short inactive methylated thiol-PEG can be optimized for maximal functional binding.
- the surface may then be activated through carbodiimide crosslinking in a mixture of excess NHS/EDC dissolved in MES buffer and conjugated with a capture agent molecule.
- the capture (binding) of the EVs to the sensor surface may result in a spectral shift in terms of change in transmission wavelength or a change in transmission intensity at a fixed wavelength.
- This signal can be detected by the sensor as discussed above and recorded as signal M.
- Binding of the bio-orthogonal probe to the EVs captured on the sensor [115] The bio-orthogonal probe described above can be introduced to the flow cell and allowed to contact the sensor. The bio-orthogonal probe is competitive to the drug, and it will bind to the drug’s target molecules on the EVs unless they are occupied by the drug. Such binding will cause a spectral shift in term of change in transmission wavelength or a change in transmission intensity, and the binding can be detected and recorded as signal P. [116] In some embodiments, a signal amplifying moiety is added, which is ligated to the bio- orthogonal probe via click chemistry.
- a labeling index ⁇ is defined based on the marker-specific EV binding (signal M) and the probe-induced amplification signal (signal P) in the same vesicles to account for differences in vesicle counts and composition across samples.
- This labeling index corresponds to the average probe density per sensor-captured vesicle. (FIG. 7).
- a labeling index can be used to indicate the expression level of the target in the EVs.
- the ExoSCOPE method was used to measure the labeling index of EVs derived from various cell lines with known EGFR expression (FIG.18e). The results confirmed that the analyses indeed reflect vesicular EGFR expression levels (FIG.3d and FIG.18f). [118] The ExoSCOPE assay is sensitive and highly specific; it can be directly performed on plasma samples without the need for isolating EVS therefrom.
- ExoSCOPE measurements performed directly in plasma samples showed a high specificity, as indicated in that the ExoSCOPE measurement remained similar when the sample were spiked in PBS or plasma (FIG. 18c-d).
- the assay has a limit of detection (LOD) of about 1000 probe-labeled EVs, which is 10e4 fold better than of the click ELISA assay. See FIG. 3c.
- the ExoSCOPE assay can be performed on scant exsome sample (e.g., 5 ⁇ L of native plasma) to measure multiparametric drug dynamics (i.e., protein composition and drug occupancy changes). and can be completed within one hour.
- ExoSCOPE can detect even delicate changes of drug interaction with different mutant proteins.
- the ExoSCOPE assay can be used in a number of applications, such as determining drug occupancy, screening for drug that is suitable to the patient, determining whether a patient has a mutation in a target that would affect the drug treatment, and diagnosing cancer in a patient, as further described below.
- METHOD OF DETERMINING DRUG OCCUPANCY TREATED EVS
- the methods and compositions disclosed herein can be used to determine drug occupancy over time. Drug occupancy as used herein, refers to that percentage of the target molecules (e.g., EGFR) on the cell that are bound by a drug (e.g., afatinib).
- the mechanism of action is through binding to a target on the tumor cell, a higher drug occupancy indicates that the drug is more likely to be effective.
- the method measures binding of a drug to a target in a subject that has been treated with a drug over a treatment period.
- the drug occupancy can be determined within 24 hours after the drug administration, which provides fast and accurate determination whether the drug is effective and aid in the selection of the most suitable treatment plan for the patient.
- the method measures the binding of a drug to a target in a subject that has been treated with a drug over a treatment period.
- the method includes providing a probe that is capable of competing with the drug in binding to the target and contacting the probe with extracellular vesicles (EVs) from samples obtained from the subject at different time points of the treatment period and detecting the binding of the probe to the EVs in the samples.
- EVs extracellular vesicles
- the drug can be determined as effective if the binding of the probe to the EVs at a later time point in the treatment period is higher relative to the binding of the probe to the EVs at an earlier time point. Conversely, the drug can be determined as ineffective if the binding of the probe to the EVs at a later time point in the treatment period is lower relative to the binding of the probe to the EVs at an earlier time point.
- the EV samples are taken from the patient at regular intervals from the start of the treatment period, and the detection of the increase in drug occupancy at a later time point as compared to an earlier time point indicates that the drug is effective.
- the patient is administered with the drug on a regular interval (e.g., daily, every other day, or every three days) and the EV samples are also taken at regular intervals from the start of the treatment period, e.g., within 24 hours from each of the at least two administrations.
- the patient is administered with the drug every 24 hours and the EV samples are obtained between 0.5 and 24 hours, between 5 and 24 hours, or between 8 and 24 hours after every drug administration, but before the next drug administration.
- patient blood are drawn at the desired time points described above, and plasma are prepared from these blood samples.
- the plasma samples contain the EVs and can be collected and stored at -80°C before use in the ExoSCOPE assay disclosed herein.
- the EVs (e.g., the plasma samples) from patients who have received drug treatment are captured on the sensor by a capturing agent as described above and the EVs are incubated with a probe to determine drug occupancy. Contacting EVs with the probe and capturing the EVs on the sensor may be performed in any order. In some embodiments, the EVs are captured on the sensor and the probe is applied to the EVs that have been captured on the sensor. In some embodiments, the EVs are first incubated with the probe before the probe bound-EVs are captured on the sensor.
- the EVs are first captured before contacting the probe, and the capture of the EVs to the sensor surface result in a spectral shift in terms of change in transmission wavelength or a change in transmission intensity at a fixed wavelength.
- This signal can be detected by the sensor as discussed above and recorded as signal M.
- the probe binding to the target molecules on the EVs (unless they are occupied by the drug) will cause a spectral shift in term of change in transmission wavelength or a change in transmission intensity.
- a signal amplifying moiety comprising an enzyme is then be added, and the signal amplifying moiety is ligated to the probe via click chemistry as described above. Appropriate substrates are added to the sensor and react with the enzyme to produce insoluble optical product deposited on the sensor.
- the deposit of the optical product on the sensor causes lead to plasmonic signal enhancement and a red shift in the resultant transmission optical spectrum, which is detected and recorded as signal P. Because the amplification occurs on the sensor where the EVs are bound, this amplification is referred to as in situ amplification of the signal corresponding to the binding of the probe to the target molecule on the EVs.
- the EVs are first incubated with the probe and the probe binds to the EVs which are not fully occupied by the drug. The EVs (including those are bound by the probe and those are not bound by the probe) are captured on the sensor.
- the capture (binding) of the EVs to the sensor surface results in a spectral shift in terms of change in transmission wavelength or a change in transmission intensity at a fixed wavelength.
- This signal can be detected by the sensor as discussed above and recorded as signal M.
- a signal amplifying moiety comprising an enzyme can then be added, which is ligated to the probe.
- Appropriate substrates are added to the sensor and react with the enzyme to produce insoluble optical product deposited on the sensor.
- the deposit of the optical product on the sensor lead to plasmonic signal enhancement and a red shift in the resultant transmission optical spectrum, which is detected and recorded as signal P [125]
- the probe labeling index ⁇ is determined based on the ratio of signal P to signal M, as described above.
- the probe labeling index ⁇ is normalized against a reference probe labeling index ⁇ 0 to produce a normalized probe labeling index.
- the reference probe labeling index ⁇ o refers to the probe labeling index determined on a control sample, e.g., a sample from a subject that has not been treated with the drug.
- Drug occupancy is inversely related the probe labeling index.
- a drug occupancy index is useful for a study on longitudinal treatment monitoring, i.e., a study to monitor the effect of a treatment over the entire or a portion of the treatment period.
- a drug occupancy index is determined for EV samples taken from patients at a different time points after start of the treatment; an increase or no change in the drug occupancy index at a later time points as compared to the drug occupancy index at an earlier time point indicates that the drug is effective; conversely, a decrease in the drug occupancy index as a later timepoint as compared to the drug occupancy at an early time point indicates that the drug is ineffective.
- Multiplexed detection of protein-typed extracellular vesicle subpopulations [128] In some aspects, the invention involves multiplexed detection of marker-typed extracellular vesicle subpopulations and respective drug occupancy within these extracellular vesicle subpopulations.
- Bioassays can be developed for the multiplexed ExoSCOPE workflow to marker- type and measure drug occupancy in molecular subpopulations of extracellular vesicles.
- a multiplex drug occupancy index determination can be performed. For example different subpopulations of EVS are captured on the sensor, and each subpopulation are bound by a different capture agent immobilized on a discrete area on the sensor, such that the EVs bind to two or more different capture agents. Each of the two or more different capture agents can bind to EV subpopulations expressing a different marker, e.g., HER2, EGFR, EpCAM, and MUC1.
- Drug occupancy can be determined on each of the EV subpopulations at a time point, e.g., within 24 hours, e.g., between 5 and 24 hours, between 8 and 24 hours after the administration of the drug.
- a drug occupancy index can be determined for each population and a plurality of occupancy indexes for all EV subpopulations can be generated.
- a composite drug occupancy index can be determined based on the combination of a plurality of occupancy indexes.
- the compositions drug occupancy index is generated from the plurality of drug occupancy indexes using a multiple linear regression model.
- the compositions drug occupancy index is calcuated from at least two, at least three, at least four, or at least five individual drug occupancy indexes using the multiple regression model; each individual drug occupancy is determined as described.
- the following exemplifies to calculate a composition and drug occupancy index based on three drug occupancy indexes, X1, X2, and X3, determined on EV subpopulations that are captured by three different capture reagents.
- three capture reagents that bind to three different markers, each selected from the group consisting of CD63, CD9, CD81, HER2, MUC1, EpCAM, and EGFR.
- a longitudinal treatment monitoring study can be conducted to determine the composite drug occupancy index at different time points after treatment; an increase or no change in the composite drug occupancy index at a later time points as compared to the composite drug occupancy index at an earlier time point indicates that the drug is effective; conversely, a decrease in the composite drug occupancy index as a later timepoint as compared to the compositions drug occupancy index at an earlier time point indicates that the drug is ineffective.
- One illustrative example of using the composite drug occupancy index to determining the efficacy of lung cancer therapy is shown in Example 6.
- Example 6 Further multiplexed ExoSCOPE on time-dependent changes in EV drug occupancy ( ⁇ ) could effectively distinguish responders from non-responders (P ⁇ 0.0005) undergoing targeted treatment of EGFR inhibitor.
- the difference could be observed as early as in 24 hours after treatment initiation, while responder and non-responder status was clinically determined at the end of the treatment (day-21) by tumor volumetric imaging.
- the other changes in EV protein marker composition ( ⁇ M) or total drug concentration in blood plasma ( ⁇ D) showed insignificant differences between the two clinical groups.
- the technology could be directly applied to clinical plasma samples and accurately detected lung cancer patients, providing drug occupancy signatures that could distinguish treatment efficacy.
- DRUG SCREENING [133]
- the methods and compositions disclosed carrying can also be used for drug screening. In my embodiments a method provided herein can be used to compare the potency of a first drug relative to a second drug on a subject.
- the first drug is a test drug of unknown potency and the second drug is a reference drug with known potency in treating the cancer.
- the method comprises contacting EV samples of a subject with the first drug and the second drug used at the same concentration separately. A bio-orthogonal probe that is competitive to the first and the second drug in binding to the target is added to the EVs that have been contacted with the first drug or the second drug. The method further comprises detecting the binding of the probe to the EVs. A lower binding of the probe to the EVs that have been contacted with the first drug relative to the second drug indicates that the first drug is more potent than the second drug.
- a higher binding of the probe to the EVs that have been contacted with the first drug relative to the second drug indicates that the first drug is less potent than the second drug.
- the binding of the probe to the EVs may be determined based on the probe labeling index or the drug occupancy index, the two inversely related parameters. [135] In some embodiments, the binding of the probe to the EV’s is determined based on the probe labeling index and comparing the potency of the first drug to a second drug involves contacting the EVs with varying concentrations of the first drug and varying concentrations of a second drug, respectively.
- the method further comprises adding a probe to the EVs that have been contacted with the first or the second drug and determining the probe labeling index at each concentration of the first or second drug. Then an IC 50 of the probe labeling index of the first drug and an IC 50 of the second drug are calculated. The method then determines the first drug is less potent than the second drug if the IC 50 of the probe labeling index of the first drug is lower than the second drug and determines the first drug is more potent than the second drug if the IC 50 of the probe labeling index of the first drug is higher than the second drug.
- the binding of the probe to the EV’s is determined based on drug occupancy index and comparing the potency of the first drug to a second drug involves contacting the EVs with varying concentrations of the first drug and varying concentrations of a second drug, respectively.
- the method further comprises adding a probe to the EVs that have been contacted with the first or the second drug and determining the drug occupancy index at each concentration of the first or second drug. Then an IC 50 of the drug occupancy index of the first drug and an IC 50 of the drug occupancy index of the second drug are calculated.
- the method determines the first drug is more potent than the second drug if the IC 50 of the drug occupancy index of the first drug is lower than the second drug and determines the first drug is less potent than the second drug if the IC 50 of the drug occupancy index of the first drug is higher than the second drug.
- three EGFR inhibitors, afatinib, osimertinib and erlotinib, each in an increasing concentration are incubated with EVs. Drug occupancy index or determined using the ExoSCOPE method disclosed herein.
- Afatinib, osimertinib and erlotinib demonstrated IC 50 of 1.9 nM, 11.5 nM, 24.4 nM, which indicates that afatinib is most potent EGFR inhibitor among the three.
- the patient is treated with the more potent drug.
- PATIENT SCREENING Methods and compositions disclosed herein can also be used to detect a mutation in a subject that is related to drug resistance.
- a method of detecting the mutation in a target in a subject comprises: i) contacting an EV sample from the patient with a drug that binds the wild type target; ii) adding a probe to the EVs samples (i.e., a sample from the patient containing EVs) that have contacted with the drug, and the probe is competitive to drug in binding to a wild type target; iii) determining the IC 50 of drug occupancy for EVs from the patient as compared to a control EV sample expressing wild type target; and iv) determining that the subject has a mutation in the target if the IC 50 of drug occupancy for the EV sample from the patient is less than the IC 50 of drug occupancy for the control EV sample.
- the EVs are captured on the sensor via binding to a capture agent immobilized on the sensor.
- the capture agent is an antibody that is against one or more proteins selected from the group consisting of CD63, CD81, CD9, HER2, LAMP-1, Alix, HSP90, an Flotillin 1, a TSG101, EGFR, EpCAM, and MUC1 [139]
- the mutation is an EGFR mutation.
- the method of detecting mutations in EGFR in a subject comprises: i) contacting an EV sample from the patient with a drug that targets EGFR; ii) adding a probe to the EV samples that have contacted with the drug, and the probe is capable of competing with the drug in binding to the EGFR in the EVs; iii) determining the IC 50 of drug occupancy for EVs from the patient as compared to a control EV sample expressing the wild type EGFR; and iv) determining that the subject has a mutation in the EGFR if the IC 50 of drug occupancy for the EV sample from the patient is less than the IC 50 of drug occupancy for the control EV sample.
- the EVs are captured on the sensor via binding to a capture agent immobilized on the sensor.
- the capture agent is antibody against one or more proteins selected from the group consisting of CD63, CD81, CD9, HER2, LAMP-1, Alix, HSP90, Flotillin 1, a TSG101, HER2, EGFR, EpCAM, and MUC1.
- METHOD OF DIAGNOSIS/PROGNOSIS (UNTREATED EVS) [140] Also provided herein are methods and compositions for diagnosing a lung cancer in a subject.
- the method comprises contacting a probe that binds EGFR with extracellular vesicles (EVs) from a sample obtained from the subject.
- the probe is capable of competing with an EGFR inhibitor in binding to EGFR, wherein the EGFR inhibitor is any one of afatinib, osimertinib, erlotinib, dacomitinib, CNX2006, and WZ4002.
- the EVs are captured by a capture agent immobilized on a sensor, and the capture agent binds to a cancer marker that is preferentially expressed the lung cancer than normal cells.
- the capture agent’s binding to cancer marker does not substantially interfere with the binding of the probe to the cancer marker on the EVs.
- the method further comprises detecting the signal associated with binding of the probe to the EVs, and detecting a signal greater than a threshold indicates that subject has the a lung cancer.
- the threshold is a signal associated with the binding of the probe to EVs from an individual that is free of the type of lung cancer under the same conditions.
- EVs used for the diagnosis may be captured on the sensor before or after contacting the probe.
- the cancer marker that is preferentially expressed in lung cancer than normal tissue include, but are not limited to, HER2, MUC1, EpCAM, and EGFR. COMPOSITE SIGNATURE FOR CANCER DIAGNOSIS [143]
- the ExoSCOPE technology enables detection of protein markers on the same platform, enabling biomarker discovery and direct clinical application for different diseases.
- identification of EGFR, EpCAM and MUC1 as marker combination in circulating extracellular vesicles for detecting lung cancer and providing drug occupancy signatures to distinguish treatment efficacy is obtained from the patients, and the EV subpopulations expressing two or more cancer markers selected from the group consisting of EGFR, EpCAM and MUC1 are captured on the plasmonic sensor disclosed above.
- a composite drug occupancy index (or a composite cancer signature) can be generated using a cross- trained regression model based on the ExoSCOPE analyses of the cancer markers and validated the model using leave-one-out cross-validation, as described above.
- a composition and drug occupancy index greater than a threshold indicates the patient has lung cancer.
- the threshold is the composite drug occupancy index determined on EVs from an individual that is free of the type of lung cancer under the same conditions.
- the ExoSCOPE composite cancer signature demonstrated the best accuracy for disease classification – the area under the curve (AUC) of the assay is typically at least 0.8 or at least 0.9. see (FIG.24).
- the acuracy of using ExoSCOPE composite cancer signature on three putative cancer markers (EGFR, EpCAM and MUC1) as well as pan-extracellular vesicle marker (CD63) for the lung cancer diagnosis demonstrated the best accuracy, represented by area under curve AUC is 0.982, see FIG.5b.
- the application discloses a robust, blood- based approach involving EVs for the molecular characterization of drug-target interactions, even of solid tumors.
- the ExoSCOPE platform a dedicated system for multiparametric analysis of EV drug dynamics, directly in clinical blood samples.
- the ExoSCOPE In comparison to other analytical technologies, the ExoSCOPE not only presents distinct technology advances, but also expands the clinical reach of EVs for activity-based monitoring of drug-target interactions.
- the methods and compositions related to ExoSCOPE leverage synergistic assay and sensor development and is a technology advancement in the field of monitoring drug-target interactions.
- the ExoSCOPE employs amplified labeling with bio-orthogonal probes; the competitive probes not only enable specific labeling of whole vesicles, but also provide reactive handles for enzymatic signal amplification in situ, to locally produce optical deposits for enhanced plasmonic sensing.
- the platform supports precise spatial engineering.
- EVs are protein-typed and probe-amplified within the cavities of plasmonic nanoring resonators; all molecular reactions are mapped accordingly to exploit local electromagnetic hotspots. Drawing on this assay-sensor synergy, the platform achieves superior analytical performance. While drug-target interactions are commonly evaluated for drug discovery and development (i.e., on recombinant proteins, cell line and/or animal models) (Refs. 34 and 35), such measurements cannot be readily performed in patients during clinical studies.
- the ExoSCOPE is sensitive and measures multiparametric drug dynamics (i.e., protein composition and drug occupancy changes) directly in a small amount of EV specimen (5 ⁇ L of clinical plasma sample in 1 hour).
- multiparametric drug dynamics i.e., protein composition and drug occupancy changes
- the ExoSCOPE not only reveals new insights about vesicular composition, but also introduces many clinical opportunities.
- biophysical or biochemical markers e.g., vesicle counts or total proteins
- the ExoSCOPE monitors activity-based drug dynamics and reveals integrative metrics that closely correlate to cellular drug effects (e.g., drug occupancy and potency). Unlike conventional blood pharmacologic analyses (e.g., PK/PD), which measure total drug concentration or ensemble biochemical responses in blood (i.e., lack tumor-specificity) (Tuntland et al. (2014)), the ExoSCOPE interrogates distinct subpopulations of circulating EVs to unveil cell- specific drug effects. When applied for clinical monitoring, the ExoSCOPE-developed signatures accurately reflect disease status and rapidly distinguish treatment outcomes. [148] With its enhanced capabilities for multiparametric evaluation of vesicle drug dynamics, the methods and compositions disclosed herein could be used to investigate complex drug interactions.
- the technology could be applied to discover new EV composite signatures, across different drugs and vesicle molecular subtypes (e.g., derived from different cell origins) (Lim et al., Adv Biosyst e1900309 (2020); Lim et al., ACS Sens 5, 4-12 (2020)), in a spectrum of diseases (e.g., cancers, cardiovascular diseases, and neurological diseases).
- vesicle molecular subtypes e.g., derived from different cell origins
- diseases e.g., cancers, cardiovascular diseases, and neurological diseases.
- Such signatures could provide new metrics for correlating to various (un)desired drug effects (e.g., on-target potency and off-target side effects) (Borrebaeck (2017)) thereby improving patient stratification and rationalizing drug selection.
- Embodiments [150] This disclosure provides the following non-limiting embodiments: [151] Embodiment 1.
- a method of measuring binding of a drug to target molecules in a subject that has been treated with a drug over a treatment period comprises: contacting a probe with extracellular vesicles (EVs) from samples obtained from the subject at different time points of the treatment period, wherein the probe is capable of competing with the drug in binding to the target molecules in the EVs, and detecting the binding of the probe to the EVs in the samples, wherein a decrease in the binding of the probe to the EVs as treatment period progresses indicates an increase in the binding of the drug to the target molecules in the subject.
- EVs extracellular vesicles
- contacting the probe with EVs from the samples obtained from the subject comprises: for each sample, i) contacting the EVs from the sample with a sensor, wherein the EVs are captured to the sensor, ii) contacting the probe with the EVs captured on the sensor, wherein the probe binds to target molecules on the EVs that are not already bound by the drug, wherein the binding of the probe to the target molecules results in a signal P.
- the signal P is in situ enzymatic amplification of signal corresponding to the binding of the probe to the target molecules.
- Embodiment 5 The method of embodiment 4, wherein the determining the binding of the drug to the target at different time points in the treatment period comprises: determining a probe labeling index ⁇ based on the ratio of the signal P to the signal M, normalizing the probe labeling index ⁇ to a reference probe labeling index ⁇ 0 to produce a normalized probe labeling index ⁇ / ⁇ 0, wherein the reference probe labeling index ⁇ 0 is determined on a control sample, wherein the control sample is obtained from a subject that has not been treated with the drug, determining a drug occupancy index based on the normalized probe labeling index.
- Embodiment 6 The method of any of embodiment 1-5, wherein the different time points are at intervals after start of the treatment period, wherein the method comprises determining drug occupancy at each time point, and determining the drug is effective if the drug occupancy at a later time point is higher than the drug occupancy at an earlier time point.
- Embodiment 7. The method of any one of embodiments 2-6, wherein the EVs are captured by binding to one or more capture agents immobilized on the sensor.
- Embodiment 7 wherein the captured EVs comprise two or more different subpopulations, each subpopulation binding to a different capture agent immobilized on a discrete area on the sensor, thereby the captured EVs bind to two or more different capture agents, wherein the method comprises calculating a composite drug occupancy based on the drug occupancies determined for the two or more different subpopulations using a multiple linear regression model.
- Embodiment 9 The method of embodiment 8, wherein the two or more different capture agents are selected from the group consisting of an anti-CD63 antibody, an CD9 antibody, an CD81 antibody, an HER2 antibody, an MUC1 antibody, an EpCAM antibody, and an EGFR antibody.
- a method of comparing the potency of a first drug relative to the potency of a second drug on a subject comprising: contacting the first drug and the second drug with extracellular vesicles (EVs) obtained from a sample of the subject separately, adding a probe to the EVs that have been contacted with the first drug and to the EVs that have been contacted with the second drug, wherein the probe is capable of competing with both the first drug and the second drug in binding to the target molecules in the EVs, and detecting the binding of the probe to the EVs that have been contacted with the first drug and EVs that have been contacted with the second drug, wherein a lower binding of the probe to the EVs that have been contacted with the first drug relative to the second drug indicates that the first drug is more potent than the second drug, and wherein a higher binding of the probe to the EVs that have been contacted with the first drug relative to the second drug indicates that the first drug is less potent than the second drug in the samples.
- EVs extra
- Embodiment 11 The method of embodiment 10, wherein the contacting the EVs with varying increasing concentrations of a first drug and a second drug, contacting the EVs that have been contacted with varying increasing concentrations of the first or the second drug with a probe, determining the drug occupancy at each concentration of the first and second drug, determining an IC 50 of the drug occupancy of the first drug and an IC 50 of the drug occupancy of the second drug, determining that the first drug is more potent than the second drug if the IC 50 of the drug occupancy of the first drug is lower than that of the second drug, or determining the first drug is less potent than the second drug if the IC 50 of of the drug occupancy of the first drug is higher than that of the second drug.
- Embodiment 12 The method of embodiment 10-11, wherein the method further comprises treat the subject with the first drug, if the first drug is determined to be more potent than , the second drug, or treat the subject with the second drug if the second drug is determined to be more potent than the first drug..
- Embodiment 13 Embodiment 13.
- a method of detecting mutations in EGFR in a subject comprising: i) contacting an EV sample from a patient with a drug that targets the wild type EGFR, ii) adding a probe to the EVs samples that have contacted with the drug, wherein the probe is capable of competing with the drug in binding to the wild type EGFR iii) determining an IC 50 of drug occupancy for EVs from the patient as compared to that of control EVs expressing the wild type EGFR, and iv) determining that the subject has a mutation in the EGFR if the IC 50 of drug occupancy for the EV sample from the patient is less than the IC 50 of drug occupancy for the control EVs.
- Embodiment 15 The method of embodiment 14, wherein the capture agent is an antibody that is against one or more proteins selected from the group consisting of CD63, CD81, CD9, HER2, LAMP-1, Alix, HSP90, an Flotillin 1, a TSG101, EGFR, EpCAM, and MUC1.
- Embodiment 16 is an antibody that is against one or more proteins selected from the group consisting of CD63, CD81, CD9, HER2, LAMP-1, Alix, HSP90, an Flotillin 1, a TSG101, EGFR, EpCAM, and MUC1.
- a method of diagnosing a lung cancer in a subject comprising: contacting a probe with extracellular vesicles (EVs) from a sample obtained from the subject, wherein the EVs are captured by a capture agent immobilized on a sensor, wherein the capture agent binds to a cancer marker on the EVs, wherein the cancer marker is preferentially expressed in lung cancer than normal cells, wherein the probe binds to EGFR on the EVs, wherein the binding of the capture agent to the cancer marker does not substantially interfere with the binding of the probe to the cancer marker on the EVs, detecting a signal associated with binding of the probe to the EVs, and determining subject has the lung cancer if the signal is greater than a control.
- EVs extracellular vesicles
- Embodiment 17 The method of embodiment 16, wherein the EVs are immobilized on the sensor before contacting the probe.
- Embodiment 18 The method of embodiment 16, wherein the EVS are immobilized on the sensor after contacting the probe.
- Embodiment 19 The method of any of embodiments 16-18, wherein the cancer marker is one or more of MUC1, EpCAM, and EGFR.
- Embodiment 20 The method of any one of embodiments 16-19, wherein the capture agent is an antibody against any one or more of MUC1, EpCAM, and EGFR.
- Embodiment 21 Embodiment 21.
- Embodiment 22 The method of any one of embodiments 16-21, wherein the control is a signal associated with the binding of the probe to EVs from an individual that is free of the type of cancer under the same conditions.
- Embodiment 23 The method of any one of embodiments 1-22, wherein the samples are bodily fluid or tissue biopsy.
- Embodiment 24 The method of any one of embodiments 1-22, wherein the samples are bodily fluid or tissue biopsy.
- Embodiment 25 The method of any one of embodiments 2-24, wherein the sensor is a plasmonic sensor.
- Embodiment 26 The method of any one of embodiments 2-24, wherein the sensor is the sensor of embodiments 35.
- Embodiment 27 The method of any one of embodiments 1-25, wherein the drug is an EGFR inhibitor.
- Embodiment 28 The method of any one of embodiments 1-25, wherein the drug is an EGFR inhibitor.
- Embodiment 29 A sensing element comprising nanogap structures patterned on a conductive layer that is deposited on a glass substrate, wherein the nanogap structures are patterned to form nanogaps between adjacent nanostructures, and wherein the average size of nanogap is 20 to 500 nm, wherein illumination of the nanogap structures produces a surface plasmon resonance.
- Embodiment 30 A sensing element comprising nanogap structures patterned on a conductive layer that is deposited on a glass substrate, wherein the nanogap structures are patterned to form nanogaps between adjacent nanostructures, and wherein the average size of nanogap is 20 to 500 nm, wherein illumination of the nanogap structures produces a surface plasmon resonance.
- Embodiment 31 The sensing element of embodiment 29 or 30, wherein the nanogap structures are nanorings, wherein the nanogaps are formed between an outer circular shape and an inner circular shape wherein the outer circular shape has an outer diameter in a range from 200 nm to 500 nm, and /or the inner circular shape has an inner diameter in a range from 30 nm to 250 nm.
- Embodiment 32 The sensing element of embodiment any of embodiments 29-31, wherein the conductive layer comprises a material selected from the group consisting of a silver, gold, copper, titanium, aluminum, and chromium.
- Embodiment 33 The sensing element of any of embodiments 29-32, wherein the nanogap structures form a periodic lattice.
- Embodiment 34 The sensing element of any one of embodiments 29-33, wherein the sensing element further comprises a capture agent immobilized on the glass substrate in the nanoring gap.
- Embodiment 35 A sensor comprising an array of the sensing element of any one of embodiments 29-34.
- Embodiment 36 Embodiment 36.
- a microfluidic system comprising: a flow cell, wherein the flow cell comprises a sensor array comprising a plurality of sensing elements of embodiment 29, microfluidic channels for introducing samples into the sensor array; and a light source, wherein the light source is arranged to illuminate the sensor array.
- Embodiment 37 A probe that is capable of competing with a drug in binding to its target, wherein the probe contains a tag, wherein the tag can ligate to an enzyme, and wherein the enzyme is capable of catalyzing a reaction to produce an insoluble optical product and producing a detectable signal.
- Embodiment 38 The probe of embodiment 37, wherein the probe is a click probe.
- Embodiment 39 Embodiment 39.
- Embodiment 40 The probe of embodiment 37 or 38, wherein the enzyme is conjugated to tetrazine or dibenzocyclooctyne (DBCO).
- Embodiment 41 The probe of any one of embodiments 37-40, wherein the enzyme is tetrazine-conjugated horseradish peroxidase (HRP).
- Embodiment 42 The probe of any one of embodiments 37-41, wherein the drug is an EGFR inhibitor and its target is EGFR, and the probe has substantially similar binding and/or functional activity to the EGFR inhibitor.
- Embodiment 43 Embodiment 43.
- Embodiment 44 The probe of any one of embodiments 38-43, wherein the click probe has a structure of [195] [196] Embodiment 45.
- Embodiment 46 The probe of embodiment 44, wherein R is selected from the group consisting of [198] [199] Embodiment 47.
- the probe of embodiment 42 or 43, wherein the EGFR inhibitor is selected from the group consisting of afatinib, osimertinib, erlotinib, dacomitinib, CNX2006, and WZ4002.
- H3255, PC9 and H1975 cells were cultured in Roswell park memorial institute medium (RPMI-1640, Hyclone), while A431 was cultured in Dulbecco's modified eagle medium (DMEM, Hyclone), supplemented with 10% (v/v) of fetal bovine serum (FBS, Gibco) and 1% (v/v) of penicillin-streptomycin (Gibco) in a humidified 37 °C incubator with 5% CO 2 . All cell lines were tested and free of mycoplasma contamination (MycoAlert Mycoplasma Detection Kit, Lonza, LT07- 418). [203] EV collection and characterization.
- DMEM Dulbecco's modified eagle medium
- FBS fetal bovine serum
- Gibco penicillin-streptomycin
- EVs at passages 1–15 were cultured in vesicle- depleted medium (with 5% depleted FBS) for 48 hr, before vesicle collection and characterization according to MISEV guidelines (Théry et al. (2016)). All media containing EVs were filtered through a 0.2- ⁇ m membrane filter (regenerated cellulose, Millipore). For conventional analysis (e.g., Western blotting and ELISA), EVs were enriched by differential centrifugation (first at 10,000 g and subsequently at 100,000 g). For ExoSCOPE analysis, all samples were used directly for measurements. All EV samples were stored at -80 °C before further analysis.
- NTA nanoparticle tracking analysis
- ExoSCOPE sensor design We performed full three-dimensional, finite-difference time- domain (FDTD) simulations to optimize the sensor design (FDTD solutions, Lumerical). Periodic boundary conditions in x- and y-directions were used to simulate an infinite array of periodic nanorings. Nanoring arrays with different periodicities and geometries were illuminated with a plane wave from the bottom side. A non-uniform mesh with a minimum grid size of 2 nm was applied. In determining the optimal sensor geometry (FIG.9a), we used the spectral shift in response to global and local refractive index changes, respectively. [205] Sensor fabrication.
- FDTD finite-difference time- domain
- the optimized ExoSCOPE sensor design was fabricated on 2.5 x 2.5 cm glass substrate.
- the substrate was spin-coated (4000 r.p.m. for 70 s) with a 180-nm layer PMMA 495k, followed by hard baking on a hotplate at 170 °C for 5 min.
- a second 180-nm layer PMMA 495k was spin-coated (4000 r.p.m. for 70 s) onto the substrate, and post baked at 180 °C for 2 min.
- a thin layer of Espacer was then applied to the surface to improve the substrate conductivity.
- EBL electron-beam lithography
- MIBK organic solvent
- IPA isopropyl alcohol
- an adhesion layer Ti/Au; 5 nm/50 nm was deposited onto the substrate, through electron-beam physical vapor deposition (AJA E Beam Evaporator System). This was followed by a lift-off process in solvent stripper (MicroChem Remover PG).
- the SU-8 mold was chemically treated by trichlorosilane vapor inside a desiccator for 15 min.
- Polydimethylsiloxane polymer (PDMS) and cross-linker were mixed at a ratio of 10:1 and casted onto the SU-8 mold and cured in an oven at 75 °C for 30 min.
- the PDMS layer was cut from the mold and assembled onto the ExoSCOPE sensor. All inlets and outlets were made with 1.1-mm biopsy punch for sample processing.
- a tungsten halogen lamp (StockerYale Inc.) was used to illuminate the ExoSCOPE sensor through a 10x microscope objective.
- Transmitted light was collected by an optical fiber and fed into a spectrometer (Ocean Optics). All measurements were performed at room temperature, in an enclosed box to eliminate ambient light interference. The transmitted light intensity was digitally recorded in counts against wavelength. For spectral analysis, the spectral peaks were determined using a custom-built R program by fitting the transmission peak using local regression method.
- In-ring surface functionalization To evaluate the location effect of molecular reactions on the ExoSCOPE detection signal, we performed differential surface functionalization to achieve bioconjugation within the nanoring gap (in-ring, SiO2) and on top of the sensor surface (atop, Au), respectively.
- the fabricated sensor was first treated with oxygen plasma to activate the dangling OH groups on SiO2 surface and improve the surface uniformity for conjugation. After treatment, the cleaned sensor was immersed into a 2% solution of (3- Aminopropyl)triethoxysilane (APTES) in ethanol for 15 min, rinsed and dried in an oven at 100 °C for 5 min. The APTES-modified sensor was washed in PBS and treated with 2.5% (v/v) glutaraldehyde in PBS for 10 min min at room temperature. Following a rinse, the sensor was reacted with 0.1 mg/ml of capture antibodies in PBS buffer at room temperature for 15 min.
- APTES 3- Aminopropyl)triethoxysilane
- the sensor was incubated in a mixture of long active (carboxylated) thiol- PEG and short inactive methylated thiol-PEG (1:3 active: inactive, 10 mM in PBS) to enable S-Au interaction.
- the modified sensor was washed in PBS and activated through carbodiimide crosslinking, in a mixture of excess NHS/EDC dissolved in MES buffer, and reacted with capture antibodies as described above. All surface modifications were spectrally monitored. All conjugated sensors were stored in PBS at 4 °C for subsequent use.
- ExoSCOPE assay We developed the ExoSCOPE assay for the direct analysis of both marker composition and drug occupancy in EVs.
- EVs were incubated with varying concentrations of drugs (e.g., afatinib, erlotinib, osimertinib, from 100 ⁇ DMSO stock) or vehicle control (DMSO) for 10 min prior to probe treatment and ExoSCOPE analysis.
- drugs e.g., afatinib, erlotinib, osimertinib, from 100 ⁇ DMSO stock
- vehicle control DMSO
- EV probe labeling index ( ⁇ ) and drug occupancy index ( ⁇ ) as follows.
- Pm probe-induced amplification signal, relative to a sample-matched control treated with analog probe without the click group.
- ⁇ m 1 – ⁇ m / ⁇ m o ; where ⁇ m o refers to that of a matched control not treated with the drug.
- the supernatant was collected and diluted to 4 mg/mL in PBS supplemented with 0.1% NP-40 and 1 mM DTT. Binding kinetics of the probe A3 to EGFR was measured through biolayer interferometry (Pall Fortebio). In brief, 100 nM of biotinylated A3 (prepared by reacting A3 with tetrazine-biotin) were immobilized onto streptavidin-functionalized interferometry sensors. After a brief washing step, the loaded biosensors were incubated for 500 s with cell lysate solutions, each with distinct EGFR expression level and/or mutation status, to measure different probe binding. This was followed by another washing step.
- vesicles were first incubated with the click probes at 37 °C for 1 h. The mixture was added to functionalized polystyrene beads. For bead functionalization, streptavidin- coated 3.0 ⁇ m polystyrene beads (Spherotech) was incubated with biotinylated anti-CD63 antibodies (10 ⁇ g/mL, BD Biosciences) in PBS with 0.5% bovine serum albumin (BSA, Sigma) overnight at 4 °C.
- BSA bovine serum albumin
- the mixture was washed and resuspended in PBS with 0.5% BSA, before being applied for EV capture.
- the bead-captured vesicles were labeled with 100 nM tetrazine-Cy5 for 5 min at room temperature and washed.
- FITC and APC fluorescence were assessed using a CytoFLEX Flow Cytometer (Beckman Coulter). Mean fluorescence intensities of all cells/beads, excluding debris, was determined using FlowJo (version 10.6.1), and biomarker expression levels were normalized against isotype control antibodies while probe expression levels were normalized against no-drug no-probe control.
- Protein lysates (10 ⁇ g) were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto polyvinylidene fluoride membrane (PVDF, Invitrogen, Carlsbad, CA), and immunoblotted with antibodies against protein markers: EGFR (Cell Signaling, Danvers, MA), CD63 (Santa Cruz Biotechnology Dallas, TX), LAMP-1 (BD Biosciences, San Jose, CA), Alix (Cell Signaling), HSP90 (Cell Signaling), Flotillin 1 (BD Biosciences), TSG101 (BD Biosciences), GM130 (Cell Signaling), Calnexin (BD Biosciences), phopho-EGFR (Y1068, Cell Signaling), phospho-Gab1 (Y621, Cell Signaling) , phospho-PLC ⁇ 1 (Y783, Cell Signaling), phospho-Akt (S473, Cell Signaling), phospho-Shc (Y239/240, Cell Signaling), actin
- Enzyme-linked immunosorbent assay (ELISA). Capture antibodies (5 ⁇ g/mL) were adsorbed onto ELISA plates (ThermoFisher Scientific) and blocked in PBS containing 1% BSA (Sigma, St. Louis, MO) before incubation with samples. After washing with PBST (PBS with 0.05% Tween 20), detection antibodies (2 ⁇ g/mL) were added and incubated for 2 hr at room temperature.
- GI50 half maximal inhibition of proliferation
- cells were seeded at a density of 20,000 cells per well in a 96-well plate overnight, and treated with the drug or vehicle control (final concentration of 0.1% DMSO) for 3 days.
- Cell viability was assessed using the [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium inner salt (MTS) cell proliferation assay (Promega).
- MTS tetrazolium inner salt
- ExoSCOPE sensors functionalized with respective antibodies: EGFR (Merck), EpCAM (R&D Systems), MUC1 (Fitzgerald) and CD63 (BD Biosciences). All ExoSCOPE measurements were performed directly, without requiring any vesicle purification or isolation. Relative spectral changes were measured to determine EV marker composition. All samples were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 for 5 min at room temperature, before the ExoSCOPE enzymatic amplification to determine EV probe labeling and drug occupancy. For all measurements, we included a sample-matched negative control (IgG isotype control), as described previously.
- IgG isotype control IgG isotype control
- Plasma concentrations of erlotinib were quantified through a liquid chromatography tandem mass spectrometry method. Briefly, a liquid-liquid extraction of 50 ⁇ L of plasma samples was performed in a mixture of ethyl acetate and n-hexane (8/2, v/v), before liquid chromatography coupled through an electro spray interface to a tandem mass spectrometry in positive mode detection. The chromatographic separation was achieved through a C18 column (Thermo Scientific) with a mobile phase consisting of 2 mM ammonium acetate: methanol (20:80, v/v).
- the lower limit of detection for erlotinib was 10.4 ng/mL and the range for linearity 10.4– 2510.8 ng/mL.
- Statistical analysis All measurements were performed in triplicate, and the data displayed as mean ⁇ standard deviation. Significance tests were performed via a two-tailed Student’s t test. For inter-sample comparisons, multiple pairs of samples were each tested, and the resulting P values were adjusted for multiple hypothesis testing using Bonferroni correction. An adjusted P ⁇ 0.05 was determined as significant. Correlation analysis was performed with Pearson’s R to determine the goodness of fit in linear regressions. We further verified the agreement with Bland-Altman analysis.
- EXOSCOPE ANALYSIS OF TARGETED DRUG OCCUPANCY IN EVS.
- targeted drug binding e.g., small molecule inhibitors
- plasma membrane protein receptors e.g., EGFR
- This recycling pathway overlaps with the formation of EVs (Tan et al. (2016)).
- protein receptors are secreted into the extracellular space through nanoscale vesicles (FIG. 1a).
- Multimodal characterization of vesicles derived from lung cancer cells not only confirmed their vesicular morphology and molecular composition, but also demonstrated the presence of drug-bound protein receptors in EVs (FIG. 6).
- EVs could serve as a reflective circulating biomarker of drug dynamics, and developed the ExoSCOPE platform to evaluate EV drug occupancy as well as cellular treatment effects (FIG.1a).
- the ExoSCOPE leverages competitive target labeling by bio-orthogonal click probes and their amplified detection to measure EV drug changes (FIG. 1a). All molecular reactions are spatially patterned within plasmonic nanoring resonators for sensitive detection (FIG. 1b).
- EVs are protein-typed and probe-amplified within plasmonic sensors.
- EVs are immuno-captured onto functionalized sensors.
- probe amplification EVs with a low drug occupancy are extensively labeled with click probes.
- probes bio- orthogonal handles (trans-cyclooctene, TCO) to recruit enzymes (tetrazine-conjugated horseradish peroxidase, HRP), which catalyze in situ conversion of the soluble substrate (3,3’-diaminobenzidine, DAB) to form local, insoluble deposits on the labeled vesicles (FIG.7A).
- FIG. 1C shows the characterization of a designed ExoSCOPE click probe, a TCO derivative of the EGFR-inhibitor afatinib. Molecular modeling showed the probe’s specific interaction with the EGFR kinase active site, identical to that of the parent drug.
- the probes were synthesized based on the core structure of afatinib (BIBW2992) (Li et al. (2008)) to confer specific covalent binding to the EGFR kinase site (FIG.11A-B, see Example 8 for synthesis details).
- Each click probe contains a chemically tractable tag (i.e., azide or TCO) (Jewett & Bertozzi (2010); Patterson et al. (2014)) to enable label visualization through rapid copper-free bio-orthogonal ligation (FIG. 12A-B).
- probe A3 was subsequently prepared by introducing a glycine moiety to A2.
- H3255 cells were incubated with the respective probes, with or without afatinib. After cell lysis, the lysates were reacted with different visualization agents (i.e., dibenzocyclooctyne (DBCO)- or tetrazine- conjugated fluorescent dyes) before electrophoresis.
- DBCO dibenzocyclooctyne
- tetrazine- conjugated fluorescent dyes i.e., dibenzocyclooctyne (DBCO)- or tetrazine- conjugated fluorescent dyes
- probe A3 To validate probe A3’s direct interactions with various EGFR proteins (e.g., wild type and mutants), we employed biolayer interferometry and monitored probe-protein binding in real time, using cell lysates known to overexpress different EGFR mutations. Probe A3 demonstrated differential binding kinetics to various EGFR mutants (FIG.2D); high binding potentials (B max /K d ) were observed for distinct EGFR mutants (i.e., L858R in H3255 cells and ex19del in PC9 cells) over EGFR wild-type proteins (A431 cells), in agreement with the reported mutant selectivity of the parent drug (Li et al., (2008)).
- probe A3 demonstrated rapid and specific live-cell labeling of EGFR (>90% efficiency in 15 mins) (FIG. 14A-B), making it an ideal candidate to evaluate drug-target engagement in live cells.
- Competitive labeling of H3255 cells with various concentrations of afatinib showed drug dose-dependent decrease in probe A3 labeling, as independently validated by in-gel fluorescence, flow cytometry and click ELISA analysis, respectively (FIG. 2E and FIG. 14C-D).
- the IC 50 values derived thereof are in the similar range (1.4 – 1.6 nM), consistent with the cellular activity of afatinib (FIG. 2C).
- probe A3 Due to its specific measurement of EGFR-drug engagement, we selected probe A3 for subsequent development of the ExoSCOPE platform.
- probe A3 for in situ analysis of EV drug occupancy we first examined its ability to directly label vesicular EGFR in whole EVs. EVs were immobilized onto microbeads through anti-CD63 capture (Shao et al. (2012); Shao et al. (2015)) and incubated with probe A3, with or without afatinib.
- Multimodal analyses not only confirmed in situ probe labeling, that is afatinib- competitive and specific to vesicular EGFR (FIG.3A and FIG.6D), but also demonstrated effective probe amplification, through enzymatic deposition of insoluble optical products (FIG.15).
- FIG. 1D and FIG. 9A-D spatially-optimized plasmonic nanoring resonators
- FIG.3B spatially-optimized plasmonic nanoring resonators
- Prep-HPLC was conducted on Gilson Prep-HPLC system using reverse-phase Phenomenex Luna 5 ⁇ m C18(2) 100 ⁇ 50 ⁇ 30.0 mm column.
- High-resolution electrospray ionization mass spectra were obtained on a Bruker microTOF-Q II. All measurements were performed at room temperature (RT) of 25 °C.
- the reaction was stirred in dark at 0 °C for 30 minutes and subsequently at room temperature for 4 hrs.
- the mixture was directly purified by semi-preparative HPLC (ACN:water) to prepare the desired product as a white solid (21 mg, 42% over 2 steps).
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280025654.2A CN117098999A (en) | 2021-02-08 | 2022-02-08 | Extracellular vesicle drug analysis for real-time monitoring of targeted therapies |
EP22749349.1A EP4288781A1 (en) | 2021-02-08 | 2022-02-08 | Extracellular vesicle drug analysis for real-time monitoring of targeted therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163147170P | 2021-02-08 | 2021-02-08 | |
US63/147,170 | 2021-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022168055A1 true WO2022168055A1 (en) | 2022-08-11 |
Family
ID=82742081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/051088 WO2022168055A1 (en) | 2021-02-08 | 2022-02-08 | Extracellular vesicle drug analysis for real-time monitoring of targeted therapy |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4288781A1 (en) |
CN (1) | CN117098999A (en) |
WO (1) | WO2022168055A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012115885A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
WO2016186215A1 (en) * | 2015-05-20 | 2016-11-24 | Jsr株式会社 | Separation method, detection method, signal measurement method, disease determination method, drug efficacy assessment method, kit, liquid composition, and specimen diluent |
-
2022
- 2022-02-08 WO PCT/IB2022/051088 patent/WO2022168055A1/en active Application Filing
- 2022-02-08 EP EP22749349.1A patent/EP4288781A1/en active Pending
- 2022-02-08 CN CN202280025654.2A patent/CN117098999A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012115885A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
WO2016186215A1 (en) * | 2015-05-20 | 2016-11-24 | Jsr株式会社 | Separation method, detection method, signal measurement method, disease determination method, drug efficacy assessment method, kit, liquid composition, and specimen diluent |
Non-Patent Citations (2)
Title |
---|
MELO SONIA A., LUECKE LINDA B., KAHLERT CHRISTOPH, FERNANDEZ AGUSTIN F., GAMMON SETH T., KAYE JUDITH, LEBLEU VALERIE S., MITTENDOR: "Glypican1 identifies cancer exosomes and facilitates early detection of cancer", NATURE, vol. 523, no. 7559, 9 July 2015 (2015-07-09), pages 177 - 182, XP055646451, DOI: 10.1038/ NATURE 14581 * |
PAN S. ET AL.: "Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy", NAT. NANOTECHNOL, vol. 16, 8 March 2021 (2021-03-08), pages 734 - 742, XP037479103, DOI: 10.1038/S41565-021 -00872-W * |
Also Published As
Publication number | Publication date |
---|---|
CN117098999A (en) | 2023-11-21 |
EP4288781A1 (en) | 2023-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pan et al. | Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy | |
Shin et al. | Early-stage lung cancer diagnosis by deep learning-based spectroscopic analysis of circulating exosomes | |
JP6787976B2 (en) | Cell-wide assays and methods | |
Park et al. | Exosome classification by pattern analysis of surface-enhanced Raman spectroscopy data for lung cancer diagnosis | |
Penders et al. | Single particle automated Raman trapping analysis of breast cancer cell-derived extracellular vesicles as cancer biomarkers | |
Chin et al. | Plasmonic sensors for extracellular vesicle analysis: From scientific development to translational research | |
Zheng et al. | Gold nanoparticle-enabled blood test for early stage cancer detection and risk assessment | |
Maiolo et al. | Colorimetric nanoplasmonic assay to determine purity and titrate extracellular vesicles | |
Haun et al. | Probing intracellular biomarkers and mediators of cell activation using nanosensors and bioorthogonal chemistry | |
JP2018505138A (en) | Method for measuring ERBB signaling pathway activity for diagnosing and treating cancer patients | |
Koster et al. | Surface enhanced Raman scattering of extracellular vesicles for cancer diagnostics despite isolation dependent lipoprotein contamination | |
JP2024016122A (en) | Compositions and methods related to K180 dimethylated H1.0 protein | |
JP6301915B2 (en) | Protein expression analysis to identify genotoxic compounds | |
JP2010507384A (en) | Methods for profiling kinase inhibitors | |
JP2020517972A (en) | Method and apparatus for protein-protein interaction analysis | |
JP7094700B2 (en) | Use of extracellular free nucleosomes as biomarkers in sputum samples | |
Xie et al. | Label-free plasmon-enhanced spectroscopic HER2 detection for dynamic therapeutic surveillance of breast cancer | |
Rajput et al. | Application of surface-enhanced Raman spectroscopy to guide therapy for advanced prostate cancer patients | |
JP2023521872A (en) | Methods and systems for enhancing the optical signal of extracellular vesicles | |
Kumar et al. | Ultrasensitive melanoma biomarker detection using a microchip SERS immunoassay with anisotropic Au–Ag alloy nanoboxes | |
US20220397580A1 (en) | Method of detecting a neurodegenerative disease | |
WO2022168055A1 (en) | Extracellular vesicle drug analysis for real-time monitoring of targeted therapy | |
JP6742034B2 (en) | Quantification of proteins in multicellular tissue samples | |
Li et al. | Resonance Rayleigh scattering detection of the epidermal growth factor receptor based on an aptamer-functionalized gold-nanoparticle probe | |
Lu et al. | Rapid Evaluation of Lung Adenocarcinoma Progression by Detecting Plasma Extracellular Vesicles with Lateral Flow Immunoassays |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22749349 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022749349 Country of ref document: EP Effective date: 20230908 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280025654.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11202305982Y Country of ref document: SG |